Extrahepatic metabolism at the body's internal-external interfaces

Drug Metabolism Reviews

Volumn 46, Issue 3, 2014, Pages 291-324

  Gundert Remy, Ursula ^a   Bernauer, Ulrike ^b   Blömeke, Brunhilde ^c   Döring, Barbara ^d   Fabian, Eric ^e   Goebel, Carsten ^f   Hessel, Stefanie ^b   Jäckh, Christine ^g   Lampen, Alfonso ^b   Oesch, Franz ^h   Petzinger, Ernst ^d   Völkel, Wolfgang ⁱ   Roos, Peter H ^j  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b FEDERAL INSTITUTE FOR RISK ASSESSMENT   (Germany)

^c UNIVERSITY OF TRIER   (Germany)

^d JUSTUS LIEBIG UNIVERSITY   (Germany)

^e BASF SE   (Germany)

^f PROCTER AND GAMBLE COMPANY   (United States)

^g Knoell Co   (Germany)

^h Oesch Tox Toxicological Consulting and Expert Opinions GmbH and CoKG   (Germany)

ⁱ Bavarian Health and Food Safety Authority   (Germany)

^j RUHR UNIVERSITY BOCHUM   (Germany)

more..

Author keywords

Bladder; Intestine; Kidney; Lung; Skin; Xenobiotic metabolizing enzymes

Indexed keywords

ACYLTRANSFERASE; ALCOHOL DEHYDROGENASE; ALDEHYDE DEHYDROGENASE; ARYLAMINE ACETYLTRANSFERASE; CARBOXYLESTERASE; CARCINOGEN; CELL NUCLEUS RECEPTOR; CYSTEINE CONJUGATE BETA LYASE; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; DIMETHYLANILINE MONOOXYGENASE; ENZYME; EPOXIDE HYDROLASE; GLUCURONOSYLTRANSFERASE; GLUTATHIONE TRANSFERASE; MICRORNA; NORADRENALIN TRANSPORTER; SULFOTRANSFERASE; UNCLASSIFIED DRUG; XENOBIOTIC AGENT; XENOBIOTIC METABOLIZING ENZYME; CARRIER PROTEIN; CYTOCHROME P450;

BLADDER; CELL DIFFERENTIATION; COLON; CONJUGATION; DETOXIFICATION; ENZYME ACTIVITY; ENZYME LOCALIZATION; ENZYME MECHANISM; ENZYME REGULATION; ENZYME SPECIFICITY; EPIGENETICS; HUMAN; INTESTINE EPITHELIUM; KIDNEY METABOLISM; LIVER METABOLISM; LUNG; NONHUMAN; ONTOGENY; PROTEIN EXPRESSION; REVIEW; RISK ASSESSMENT; SMALL INTESTINE; TESTIS; TISSUE DISTRIBUTION; TISSUE METABOLISM; XENOBIOTIC METABOLISM; ANIMAL; METABOLISM; PHYSIOLOGY; TRANSPORT AT THE CELLULAR LEVEL;

ANIMALS; BIOLOGICAL TRANSPORT; CYTOCHROME P-450 ENZYME SYSTEM; HUMANS; MEMBRANE TRANSPORT PROTEINS; XENOBIOTICS;

EID: 84905465946     PISSN: 03602532     EISSN: 10979883     Source Type: Journal    
DOI: 10.3109/03602532.2014.900565     Document Type: Review

References (482)

1. Aeby P, Sieber T, Beck H, et al. (2009). Skin Sensitization to p-Phenylenediamine: The diverging roles of oxidation and N-acetylation for dendritic cell activation and the immune response. J Invest Dermatol 129:99-109.
2. Afaq F, Zaid MA, Pelle E, et al. (2009). Aryl hydrocarbon receptor is an ozone sensor in human skin. J Invest Dermatol 129:2396-2403.
3. Agarwal R, Medrano EE, Khan IU, et al. (1991). Metabolism of benzo[a]pyrene by human melanocytes in culture. Carcinogenesis 12: 1963-1966.
4. Amet Y, Berthou F, Fournier G, et al. (1997). Cytochrome P-450 4A and 2E1 expression in human kidney microsomes. Biochem Pharmacol 53:765-771.
5. Aleksa K, Matsell D, Krausz K, et al. (2005). Cytochrome P450 3A and 2B6 in the developing kidney: Implications for ifosfamide nephrotoxicity. Pediatr Nephrol 20:872-885.
6. Alexandrov K, Cascorbi I, Rojas M, et al. (2002). CYP1A1 and GSTM1 genotypes affect benzo[a]pyrene DNA adducts in smokers' lung: Comparison with aromatic/hydrophobic adduct formation. Carcinogenesis 23:1969-1977.
7. Altinisik J, Balta ZB, Aydin G, et al. (2010). Investigation of glutathione S-transferase M1 and T1 deletions in lung cancer. Mol Biol Rep 37: 263-267.
8. Altuntas TG, Zager RA, Kharasch ED. (2003). Cytotoxicity of S-conjugates of the sevoflurane degradation product fluoromethyl-2, 2-difluoro-1- (trifluoromethyl) vinyl ether (Compound A) in a human proximal tubular cell line. Toxicol Appl Pharmacol 193:55-65.
9. Anders MW. (1980). Metabolism of drugs by the kidney. Kidney Int 18: 636-647.
10. Anttila S, Hietanen E, Vainio H, et al. (1991). Smoking and peripheral type of cancer are related to high levels of pulmonary cytochrome P450IA in lung cancer patients. Int J Cancer 47:681-685.
11. Anttila S, Hirvonen A, Vainio H, et al. (1993). Immunohistochemical localization of glutathione S-transferases in human lung. Cancer Res 53:5643-5648.
12. Anttila S, Vainio H, Hietanen E, et al. (1992). Immunohistochemical detection of pulmonary cytochrome P450IA and metabolic activities associated with P450IA1 and P450IA2 isozymes in lung cancer patients. Environ Health Perspect 98:179-182.
13. Arlt VM, Glatt H, Gamboa da Costa G, et al. (2007). Mutagenicity and DNA adduct formation by the urban air pollutant 2-nitrobenzanthrone. Toxicol Sci 98:445-457.
14. Ashikaga T, Sakaguchi H, Sono S, et al. (2010). A comparative evaluation of in vitro skin sensitisation tests: the human cell-line activation test (h-CLAT) versus the local lymph node assay (LLNA). Altern Lab Anim 38:275-284.
15. Azam P, Peiffer JL, Chamousset D, et al. (2006). The cytokine-dependent MUTZ-3 cell line as an in vitro model for the screening of contact sensitizers. Toxicol Appl Pharmacol 212:14-23.
16. Baek D, Villén J, Shin C, et al. (2008). The impact of microRNAs on protein output. Nature 455:64-71.
17. Bakken PC, Evans VJ, Earle WR, et al. (1961). Establishment of a strain of human skin cells on chemically defined medium NCTC 109. Am J Hyg 73:96-104.
18. Ballatori N, Christian WV, Lee JY, et al. (2005). OSTalpha-OSTbeta: A major basolateral bile acid and steroid transporter in human intestinal, renal, and biliary epithelia. Hepatology 42:1270-1279.
19. Barchetta I, Carotti S, Labbadia G, et al. (2012). Liver vitamin D receptor, CYP2R1, and CYP27A1 expression: Relationship with liver histology and vitamin D3 levels in patients with nonalcoholic steatohepatitis or hepatitis C virus. Hepatology 56:2180-2187.
20. Barker DF, Husain A, Neale JR, et al. (2006). Functional properties of an alternative, tissue-specific promoter for human arylamine N-acetyltransferase 1. Pharmacogenet Genomics 16:515-525.
21. Barker DF, Walraven JM, Ristagno EH, et al. (2008). Quantitative tissue and gene-specific differences and developmental changes in Nat1, Nat2, and Nat3 mRNA expression in the rat. Drug Metab Dispos 36: 2445-2451.
22. Baron JM, Merk HF. (2001). Drug metabolism in the skin. Curr Opin Allergy Clin Immunol 1:287-291.
23. Baron JM, Zwadlo-Klarwasser G, Jugert F, et al. (1998). Cytochrome P450 1B1: A major P450 isoenzyme in human blood monocytes and macrophage subsets. Biochem Pharmacol 56:1105-1110.
24. Bartsch H, Ohshima H, Pignatelli B, Calmels S. (1989). Human exposure to endogenous N-nitroso compounds: Quantitative estimates in subjects at high risk for cancer of the oral cavity, oesophagus, stomach and urinary bladder. Cancer Surv 8:335-362.
25. Bauer B, Hartz AM, Fricker G, Miller DS. (2004). Pregnane X receptor up-regulation of P-glycoprotein expression and transport function at the blood-brain barrier. Mol Pharmacol 66:413-419.
26. Bebenek IG, Solaimani P, Bui P, Hankinson O. (2012). CYP2S1 is negatively regulated by corticosteroids in human cell lines. Toxicol Lett 209:30-34.
27. Beckett GJ, Howie AF, Hume R, et al. (1990). Human glutathione S-transferases: Radioimmunoassay studies on the expression of alpha-, mu-and pi-class isoenzymes in developing lung and kidney. Biochim Biophys Acta 1036:176-182.
28. Belinsky M, Jaiswal AK. (1993). NAD(P)H:quinone oxidoreductase1 (DT-diaphorase) expression in normal and tumor tissues. Cancer Metastasis Rev 12:103-117.
29. Bell DR, Bars RG, Elcombe CR. (1992). Differential tissue-specific expression and induction of cytochrome P450IVA1 and acyl-CoA oxidase. Eur J Biochem 206:979-986.
30. Bentley P, Oesch F, Glatt HR. (1977). Dual role of epoxide hydratase in both activation and inactivation. Arch Toxicol 39:65-75.
31. Berber U, Yilmaz I, Yilmaz O. (2013). CYP1A1 (Ile462Val), CYP1B1 (Ala119Ser and Val432Leu), GSTM1 (null), and GSTT1 (null) polymorphisms and bladder cancer risk in a Turkish population. Asian Pac J Cancer Prev 14:3925-3929.
32. Berendsen CL, Peters WH, Scheffer PG, et al. (1997). Glutathione S-transferase activity and subunit composition in transitional cell cancer and mucosa of the human bladder. Urology 49:644-651.
33. Berggren S, Gall C, Wollnitz N, et al. (2007). Gene and protein expression of P-glycoprotein, MRP1, MRP2, and CYP3A4 in the small and large human intestine. Mol Pharm 4:252-257.
34. Bergheim I, Bode C, Parlesak A. (2005). Distribution of cytochrome P450 2C, 2E1, 3A4, and 3A5 in human colon mucosa. BMC Clin Pharmacol 5:4.
35. Bernauer U, Appel KE, Tönnies M. (2009a). Expression and variability of microsomal epoxide hydrolase in human lung tissue. Toxicol Lett 189:S110-S111.
36. Bernauer U, Ellrich R, Heinrich-Hirsch B, et al. (2002). Expression of cytochrome P450 enzymes in human colon. IARC Sci Publ 156:487-489.
37. Bernauer U, Heinrich-Hirsch B, Tönnies M, et al. (2005a). Expression and variability of cytochrome P450 (CY) 1A enzymes in 110 individual human lung microsomes and comparison with active smoking habits. Toxicol Lett 158:S207-S208.
38. Bernauer U, Heinrich-Hirsch B, Tönnies M, et al. (2005b). Cytochrome P450 (CYP2E1)-dependent chlorzoxazone hydroxylase activities in human lung microsomes. Naunyn-Schmiedebergs Arch Pharmacol 371:R93-R94.
39. Bernauer U, Heinrich-Hirsch B, Tönnies M, et al. (2006a). Characterisation of the xenobiotic-metabolizing Cytochrome P450 expression pattern in human lung tissue by immunochemical and activity determination. Toxicol Lett 164:278-288.
40. Bernauer U, Heinrich-Hirsch B, Tönnies M, et al. (2006b). Testosterone 6-beta-hydroxylase activity in human lung microsomes: Variability and inhibition. Naunyn-Schmiedebergs Arch Pharmacol 372:P95-P96.
41. Bernauer U, Settels E, Tönnies M, Appel KE. (2009b). Detection of CYP2F1-associated enzyme activities in human lung microsomes. Naunyn-Schmiedebergs Arch Pharmacol 379:291-292.
42. Bièche I, Narjoz C, Asselah T, et al. (2007). Reverse transcriptase-PCR quantification of mRNA levels from cytochrome CYP1, CYP2 and CYP3 families in 22 different human tissues. Pharmacogenet Genomics 17:731-742.
43. Blacker KL, Olson E, Vessey DA, Boyer TD. (1991). Characterization of glutathione S-transferase in cultured human keratinocytes. J Invest Dermatol 97:442-446.
44. Blomeke B, Pietzsch T, Merk HF. (2008). Elicitation response characteristics to mono-and to N, N'-diacetyl-para-phenylenediamine. Contact Dermatitis 58:355-358.
45. Bock KW, Kohle C. (2009). The mammalian aryl hydrocarbon (Ah) receptor: From mediator of dioxin toxicity toward physiological functions in skin and liver. Biol Chem 390:1225-1235.
46. Bock KW. (2012). Human UDP-glucuronosyltransferases: Feedback loops between substrates and ligands of their transcription factors. Biochem Pharmacol 84:1000-1006.
47. Bock KW. (2013). The human Ah receptor: Hints from dioxin toxicities to deregulated target genes and physiological functions. Biol Chem 394:729-739.
48. Bonhaus DW, Gandolfi AJ. (1981). Conjugation and bioactivation of chlorotrifluoroethylene. Life Sci 29:2399-2405.
49. Bonifas J, Hennen J, Dierolf D, et al. (2010a). Evaluation of cytochrome p450 1 (CYP1) and N-acetyltransferase 1 (NAT1) activities in HaCaT cells: Implications for the development of in vitro techniques for predictive testing of contact sensitizers. Toxicol In Vitro 24:973-980.
50. Bonifas J, Scheitza S, Clemens J, Blomeke B. (2010b). Characterization of N-acetyltransferase 1 activity in human keratinocytes and modulation by para-phenylenediamine. J Pharmacol Exp Ther 334: 318-326.
51. Boobis AR, Doe JE, Heinrich-Hirsch B, et al. (2008). IPCS framework for analyzing the relevance of a noncancer mode of action for humans. Crit Rev Toxicol 38:87-96.
52. Borza A, Plottner S, Wolf A, et al. (2008). Synergism of aromatic amines and benzo[a]pyrene in induction of Ah receptor-dependent genes. Arch Toxicol 82:973-980.
53. Borst P, Oude Elferink RP (2002). Mammalian ABC transporters in health and disease. Annu Rev Biochem 71:537-592.
54. Bosetti C, Boffetta P, La Vecchia C. (2007). Occupational exposures to polycyclic aromatic hydrocarbons, and respiratory and urinary tract cancers: A quantitative review to 2005. Ann Oncol 18:431-446.
55. Boukamp P, Petrussevska RT, Breitkreutz D, et al. (1988). Normal keratinization in a spontaneously immortalized aneuploid human keratinocyte cell line. J Cell Biol 106:761-771.
56. Bourgine J, Billaut-Laden I, Happillon M, et al. (2012). Gene expression profiling of systems involved in the metabolism and the disposition of xenobiotics: Comparison between human intestinal biopsy samples and colon cell lines. Drug Metab Dispos 40:694-705.
57. Bousova I, Skalova L. (2012). Inhibition and induction of glutathione S-transferases by flavonoids: Possible pharmacological and toxico-logical consequences. Drug Metab Rev 44:267-286.
58. Brandsch M. (2009). Transport of drugs by proton-coupled peptide transporters: Pearls and pitfalls. Expert Opin Drug Metab Toxicol 5: 887-905.
59. Brandsch M, Knutter I, Bosse-Doenecke E. (2008). Pharmaceutical and pharmacological importance of peptide transporters. J Pharm Pharmacol 60:543-585.
60. Branch RA, Chern HD, Adedoyin A, et al. (1995). The procarcinogen hypothesis for bladder cancer: Activities of individual drug metabolizing enzymes as risk factors. Pharmacogenetics 5:S97-S102.
61. Branchflower RV, Nunn DS, Highet RJ, et al. (1984). Nephrotoxicity of chloroform: Metabolism to phosgene by the mouse kidney. Toxicol Appl Pharmacol 72:159-168.
62. Brand W, Boersma MG, Bik H, et al. (2010). Phase II metabolism of hesperetin by individual UDP-glucuronosyltransferases and sulfo-transferases and rat and human tissue samples. Drug Metab Dispos 38: 617-625.
63. Brauers A, Manegold E, Buettner R, et al. (2000). Cytochrome P450 isoenzyme mRNA expression pattern in human urinary bladder malignancies and normal urothelium. Cancer Detect Prev 24:356-363.
64. Buckpitt A, Boland B, Isbell M, et al. (2002). Naphthalene-induced respiratory tract toxicity: Metabolic mechanisms of toxicity. Drug Metab Rev 34:791-820.
65. Buesen R, Mock M, Nau H, et al. (2003). Human intestinal Caco-2 cells display active transport of benzo[a]pyrene metabolites. Chem Biol Interact 142:201-221.
66. Bui P, Imaizumi S, Beedanagari SR, et al. (2011). Human CYP2S1 metabolizes cyclooxygenase-and lipoxygenase-derived eicosanoids. Drug Metab Dispos 39:180-190.
67. Bui PH, Hsu EL, Hankinson O. (2009). Fatty acid hydroperoxides support cytochrome P450 2S1-mediated bioactivation of benzo[a]pyr-ene-7, 8-dihydrodiol. Mol Pharmacol 76:1044-1052.
68. Burckhardt G, Burckhardt BC. (2011). In vitro and in vivo evidence of the importance of organic anion transporters (OATs) in drug therapy. Handb Exp Pharmacol 201:29-104.
69. Butcher NJ, Tiang J, Minchin RF. (2008). Regulation of arylamine N-acetyltransferases. Curr Drug Metab 9:498-504.
70. Buters JT, Sakai S, Richter T, et al. (1999). Cytochrome P450 CYP1B1 determines susceptibility to 7, 12-dimethylbenz[a]anthracene-induced lymphomas. Proc Natl Acad Sci USA 96:1977-1982.
71. Campbell JAH, Corrigall AV, Guy A, Kirsch RE. (1991). Immunohistological localization of alpha, mu, and pi class glutathione S-transferases in human tissues. Cancer 67:1608-1613.
72. Canaparo R, Nordmark A, Finnström N, et al. (2006). Expression of cytochromes P450 3A and P-glycoprotein in human large intestine in paired tumour and normal samples. Basic Clin Pharmacol Toxicol 100:240-248.
73. Cano-Soldado P, Pastor-Anglada M. (2012). Transporters that translocate nucleosides and structural similar drugs: Structural requirements for substrate recognition. Med Res Rev 32:428-457.
74. Cantrell ET, Warr GA, Busbee DL, Martin RR. (1973). Induction of aryl hydrocarbon hydroxylase in human pulmonary alveolar macrophages by cigarette smoking. J Clin Invest 52:1881-1884.
75. Carlson GP. (2004). Comparison of the susceptibility of wild-type and CYP2E1 knockout mice to the hepatotoxic and pneumotoxic effects of styrene and styrene oxide. Toxicol Lett 150:335-339.
76. Case RAM, Hosker ME, McDonald DB, Pearson JT. (1954). Tumours of the urinary bladder in workmen engaged in the manufacture and use of certain dyestuff intermediates in the British chemical industry. I. The role of aniline, benzidine, alpha-naphthylamine, and beta-naphthylamine. Br J Ind Med 11:75-104.
77. Chen CC, Cheng YY, Chen SC, et al. (2012). Cyclooxygenase-2 expression is up-regulated by 2-aminobiphenyl in a ROS and MAPK-dependent signaling pathway in a bladder cancer cell line. Chem Res Toxicol 25:695-705.
78. Chen CJ, Chin JE, Ueda K, et al. (1986). Internal duplication and homology with bacterial transport proteins in the mdr1 (Pglycoprotein) gene from multidrug-resistant human cells. Cell 47: 381-389.
79. Cheung C, Davies NG, Hoog JO, et al. (2003). Species variations in cutaneous alcohol dehydrogenases and aldehyde dehydrogenases may impact on toxicological assessments of alcohols and aldehydes. Toxicology 184:97-112.
80. Cheung C, Smith CK, Hoog JO, et al. (1999). Expression and localization of human alcohol and aldehyde dehydrogenase enzymes in skin. Biochem Biophys Res Commun 261:100-107.
81. Chiang HC, Wang CK, Tsou TC. (2012). Differential distribution of CYP2A6 and CYP2A13 in the human respiratory tract. Respiration 84:319-326.
82. Choi K, Joo H, Campbell Jr JL, et al. (2011a). In vitro metabolism of di(2-ethylhexyl) phthalate (DEHP) by various tissues and cytochrome P450s of human and rat. Toxicol In Vitro 26:315-322.
83. Choi MK, Shin HJ, Choi YL, et al. (2011b). Differential effect of genetic variants of Na(+)-taurocholate co-transporting polypeptide (NTCP) and organic anion-transporting polypeptide 1B1 (OATP1B1) on the uptake of HMG-CoA reductase inhibitors. Xenobiotica 41:24-34.
84. Chou HC, Lang NP, Kadlubar FF. (1995). Metabolic activation of the N-hydroxy derivative of the carcinogen 4-aminobiphenyl by human tissue sulfotransferases. Carcinogenesis 16:13-17.
85. Choudhary D, Jansson I, Stoilov I, et al. (2005). Expression patterns of mouse and human CYP orthologs (families 1-4) during development and in different adult tissues. Arch Biochem Biophys 436:50-61.
86. Chu XY, Liang Y, Cai X, et al. (2009). Metabolism and renal elimination of gaboxadol in humans: Role of UDP-glucuronosyltransferases and transporters. Pharm Res 26:459-468.
87. Chun HS, Kuzmicky PA, Kado NY, Rice RH. (2000). Toxicity of Trp-P-2 to cultured human and rat keratinocytes. Chem Biol Interact 127: 237-253.
88. Clapper ML, Hoffman SJ, Tew KD. (1991). Glutathione S-transferases in normal and malignant human colon tissue. Biochim Biophys Acta 1096:209-216.
89. Cohen SM, Johannsson SL. (1992). Epidemiology and etiology of bladder cancer. Urol Clin North Am 3:421-428.
90. Cole SP, Bhardwaj G, Gerlach JH, et al. (1992). Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science 258:1650-1654.
91. Costa C, Catania S, Pasquale R De, et al. (2010). Exposure of human skin to benzo[a]pyrene: Role of CYP1A1 and aryl hydrocarbon receptor in oxidative stress generation. Toxicology 271:83-86.
92. Coughtrie MW, Burchell B, Bend JR. (1987). Purification and properties of rat kidney UDP-glucuronosyltransferase. Biochem Pharmacol 36:245-251.
93. Court MH, Zhang X, Ding X, et al. (2012). Quantitative distribution of mRNAs encoding the 19 human UDP-glucuronosyltransferase enzymes in 26 adult and 3 fetal tissues. Xenobiotica 42:266-277.
94. Crozier A, Del Rio D, Clifford MN. (2010). Bioavailability of dietary flavonoids and phenolic compounds. Mol Aspects Med 31:446-467.
95. Cruzan G, Bus J, Hotchkiss J, et al. (2012). CYP2F2-generated metabolites, not styrene oxide, are a key event mediating the mode of action of styrene-induced mouse lung tumors. Regul Toxicol Pharmacol 62:214-220.
96. Csanady GA, Guengerich FP, Bond JA. (1992). Comparison of the biotransformation of 1, 3-butadiene and its metabolite, butadiene monoepoxide, by hepatic and pulmonary tissues from humans, rats and mice. Carcinogenesis 13:1143-1153.
97. Cui X, Wu R, Zhou M, et al. (2004). Differential expression of cytochrome P450 isoforms in the lungs of septic animals. Crit Care Med 32:1186-1191.
98. Cummings BS, Zangar RC, Novak RF, et al. (2000). Cytotoxicity of trichloroethylene and S-(1, 2-dichlorovinyl)-L-cysteine in primary cultures of rat renal proximal tubular and distal tubular cells. Toxicology 150:83-98.
99. Dairou J, Petit E, Ragunathan N, et al. (2009). Arylamine N-acetyltransferase activity in bronchial epithelial cells and its inhibition by cellular oxidants. Toxicol Appl Pharmacol 236: 366-371.
100. Daniel H, Adibi SA. (1993). Transport of beta-lactam antibiotics in kidney brush border membrane. Determinants of their affinity for the oligopeptide/H+ symporter. J Clin Invest 92:2215-2223.
101. Dean M, Hamon Y, Chimini G. (2001). The human ATP-binding cassette (ABC) transporter superfamily. J Lipid Res 42:1007-1017.
102. de Jongh R, Grol S, van Koeveringe GA, et al. (2009). The localization of cyclo-oxygenase immuno-reactivity (COX I-IR) to the urothelium and to interstitial cells in the bladder wall. J Cell Mol Med 13: 3069-3081.
103. de Sousa Abreu R, Penalva LO, Marcotte EM, Vogel C. (2009). Global signatures of protein and mRNA expression levels. Mol BioSyst 5: 1512-1526.
104. de Waziers I, Cugnenc PH, Berger A, et al. (1991). Drug-metabolizing enzyme expression in human normal, peritumoral and tumoral colorectal tissue samples. Carcinogenesis 12:905-909.
105. de Waziers I, Cugnenc PH, Yang CS, et al. (1990). Cytochrome P 450 isoenzymes, epoxide hydrolase and glutathione transferases in rat and human hepatic and extrahepatic tissues. J Pharmacol Exp Ther 253: 387-394.
106. Deb S, Bandiera SM. (2009). Characterization and expression of extrahepatic CYP2S1. Expert Opin Drug Metab Toxicol 5:367-380.
107. Debiec-Rychter M, Land SJ, King CM. (1999). Histological localization of acetyltransferases in human tissue. Cancer Lett 143:99-102.
108. Decker M, Adamska M, Cronin A, et al. (2012). EH3 (ABHD9)-the first member of a new epoxide hydrolase family with high activity for fatty acid epoxides. J Lipid Res 53:2038-2045.
109. Decleves X, Jacob A, Yousif S, et al. (2011). Interplay of drug metabolizing CYP450 enzymes and ABC transporters in the blood-brain barrier. Curr Drug Metab 12:732-741.
110. Dekant W, Vamvakas S, Anders MW. (1994). Formation and fate of nephrotoxic and cytotoxic glutathione S-conjugates: Cysteine conjugate beta-lyase pathway. Adv Pharmacol 27:115-162.
111. Demierre AL, Peter R, Oberli A, Bourqui-Pittet M. (2012). Dermal penetration of bisphenol A in human skin contributes marginally to total exposure. Toxicol Lett 213:305-308.
112. Dertinger SD, Nazarenko DA, Silverstone AE, Gasiewicz TA. (2001). Aryl hydrocarbon receptor signaling plays a significant role in mediating benzo[a]pyrene-and cigarette smoke condensate-induced cytogenetic damage in vivo. Carcinogenesis 22:171-177.
113. Di YM, Chow VD, Yang LP, Zhou SF. (2009). Structure, function, regulation and polymorphism of human cytochrome P450 2A6. Curr Drug Metab 10:754-780.
114. Ding X, Staudinger JL. (2005). Induction of drug metabolism by forskolin: The role of the pregnane X receptor and the protein kinase a signal transduction pathway. J Pharmacol Exp Ther 312:849-856.
115. Dong D, Wu B. (2012). In silico modeling of UDP-glucuronosyltrans-ferase 1A10 substrates using the volsurf approach. J Pharm Sci 101: 3531-3539.
116. Döring B, Lütteke T, Geyer J, Petzinger E. (2012). The SLC10 carrier family: Transport functions and molecular structure. Curr Top Membr 70:105-168.
117. Döring B, Petzinger E. (2014). Phase 0 and phase III transport in various organs: Combined concept of phases in xenobioic transport and metabolism. Drug Metab Rev. [Epub ahead of print]. doi: 10.3109/03602532.2014. 882353.
118. Dörrenhaus A, Müller T, Roos PH. (2007). Increased CYP1A1 expression in human exfoliated urothelial cells of cigarette smokers compared to non-smokers. Arch Toxicol 81:19-25.
119. Dresser GK, Bailey DG, Leake BF, et al. (2002). Fruit juices inhibit organic anion transporting polypeptide-mediated drug uptake to decrease the oral availability of fexofenadine. Clin Pharmacol Ther 71:11-20.
120. Du L, Hoffman SMG, Keeney DS. (2004). Epidermal CYP2 family cytochromes P450. Toxicol Appl Pharmacol 195:278-287.
121. Du L, Neis MM, Ladd PA, et al. (2006b). Effects of the differentiated keratinocyte phenotype on expression levels of CYP1-4 family genes in human skin cells. Toxicol Appl Pharmacol 213:135-144.
122. Du L, Neis MM, Ladd PA, Keeney DS. (2006a). Differentiation-specific factors modulate epidermal CYP1-4 gene expression in human skin in response to retinoic acid and classic aryl hydrocarbon receptor ligands. J Pharmacol Exp Ther 319:1162-1171.
123. Duan H, Takagi A, Kayano H, Koyama I, et al. (2012). Monoclonal antibodies reveal multiple forms of expression of human microsomal epoxide hydrolase. Toxicol Appl Pharmacol 260:27-34.
124. Dzian A, Halasova E, Matakova T, et al. (2012). Lung adenocarcinoma and squamous cell carcinoma in association with genetic polymorphisms of GSTs in Slovak population. Neoplasma 59:160-167.
125. Ebert B, Seidel A, Lampen A. (2005). Induction of phase-1 metabolizing enzymes by oltipraz, flavone and indole-3-carbinol enhance the formation and transport of benzo[a]pyrene sulfate conjugates in intestinal Caco-2 cells. Toxicol Lett 158:140-151.
126. Ebert MN, Klinder A, Peters WH, et al. (2003). Expression of glutathione S-transferases (GSTs) in human colon cells and inducibility of GSTM2 by butyrate. Carcinogenesis 24:1637-1644.
127. Edler D, Stenstedt K, Ohrling K, et al. (2009). The expression of the novel CYP2W1 enzyme is an independent prognostic factor in colorectal cancer-A pilot study. Eur J Cancer 45:705-712.
128. Eklund BI, Moberg M, Bergquist J, Mannervik B. (2006). Divergent activities of human glutathione transferases in the bioactivation of azathioprine. Mol Pharmacol 70:747-754.
129. Ellero S, Chakhtoura G, Barreau C, et al. (2010). Xenobiotic-metabolizing cytochromes p450 in human white adipose tissue: Expression and induction. Drug Metab Dispos 38:679-686.
130. El Mouelhi M, Beck S, Bock KW. (1993). Stereoselective glucuronida-tion of (R)-and (S)-naproxen by recombinant rat phenol UDP-glucuronosyltransferase (UGT1A1) and its human orthologue. Biochem Pharmacol 46:1298-1300.
131. Fabian E, Vogel D, Blatz V, et al. (2013). Xenobiotic metabolizing enzymes activities in cells used for testing skin sensitization in vitro. Arch Toxicol 87:1683-1696.
132. Feldmann RJ, Maibach HI. (1970). Absorption of some organic compounds through the skin in man. J Invest Dermatol 54:399-404.
133. Filser JG, Hutzler C, Rampf F, et al. (2008). Styrene metabolism to Styrene-7, 8-oxide. Toxicol Sci 102:219-231.
134. Foth H. (1995). Expression and regulation of xenobiotic-metabolizing cytochrome P450 (CYP) enzymes in human lung. Crit Rev Toxicol 25:165-205.
135. Fromm MF. (2004). Importance of P-glycoprotein at blood-tissue barriers. Trends Pharmacol Sci 25:423-429.
136. Fry M, Vande Zande H, Green DE. (1978). Resolution of cytochrome oxidase into two component complexes. Proc Natl Acad Sci USA 75:5908-5911.
137. Fujiwara R, Nakajima M, Yamanaka H, et al. (2008). Product inhibition of UDP-glucuronosyltransferase (UGT) enzymes by UDP obfuscates the inhibitory effects of UGT substrates. Drug Metab Dispos 36: 361-367.
138. Funk C. (2008). The role of hepatic transporters in drug elimination. Expert Opin Drug Metab Toxicol 4:363-379.
139. Gaganis P, Miners JO, Knights KM. (2007). Glucuronidation of fenamates: Kinetic studies using human kidney cortical microsomes and recombinant UDP-glucuronosyltransferase (UGT) 1A9 and 2B7. Biochem Pharmacol 73:1683-1691.
140. Galijatovic A, Otake Y, Walle UK, Walle T. (1999). Extensive metabolism of the flavonoid chrysin by human Caco-2 and Hep G2 cells. Xenobiotica 29:1241-1256.
141. Garrigue JL, Ballantyne M, Kumaravel T, et al. (2006). In vitro genotoxicity of para-phenylenediamine and its N-monoacetyl or N, N-diacetyl metabolites. Mutat Res 608:58-71.
142. Gaté L, Tew KD. (2001). Glutathione S-transferases as emerging therapeutic targets. Expert Opin Ther Targets 5:477-489.
143. Gelardi A, Morini F, Dusatti F, et al. (2001). Induction by xenobiotics of phase I and phase II enzyme activities in the human keratinocyte cell line NCTC 2544. Toxicol In Vitro 15:701-711.
144. Genter MB, Marlowe J, Kevin KJ, et al. (2006). Naphthalene toxicity in mice and aryl hydrocarbon receptor-mediated CYPs. Biochem Biophys Res Commun 348:120-123.
145. Gervot L, Carrière V, Costet P, et al. (1996). CYP3A5 is the major cytochrome P450 3A expressed in human colon and colonic cell lines. Environ Toxicol Pharmacol 2:381-388.
146. Gervot L, Rochat B, Gautier JC, et al. (1999). Human CYP2B6: Expression, inducibility and catalytic activities. Pharmacogenetics 9: 295-306.
147. Gill SS, Hammock BD. (1980). Distribution and properties of a mammalian soluble epoxide hydrolase. Biochem Pharmacol 29: 389-395.
148. Gill KL, Houston JB, Galetin A. (2012). Characterization of in vitro glucuronidation clearance of a range of drugs in human kidney microsomes: Comparison with liver and intestinal glucuronidation and impact of albumin. Drug Metab Dispos 40:825-835.
149. Giuliani L, Ciotti M, Stoppacciaro A, et al. (2005). UDP-glucuronosyl- transferases 1A expression in human urinary bladder and colon cancer by immunohistochemistry. Oncol Rep 13:185-191.
150. Glaeser H. (2011). Importance of P-glycoprotein for drug-drug interactions. Handb Exp Pharmacol 201:285-297.
151. Glatt H, Bartsch I, Christoph S, et al. (1998). Sulfotransferase-mediated activation of mutagens studied using heterologous expression systems. Chem Biol Interact 109:195-219.
152. Goebel C, Hewitt NJ, Kunze G, et al. (2009). Skin metabolism of aminophenols: Human keratinocytes as a suitable in vitro model to qualitatively predict the dermal transformation of 4-amino-2-hydroxytoluene in vivo. Toxicol Appl Pharmacol 235:114-123.
153. Goedde HW, Agarwal DP, Harada S. (1980). Genetic studies on alcohol-metabolizing enzymes: Detection of isozymes in human hair roots. Enzyme 25:281-286.
154. Goetz AK, Dix DJ. (2009). Toxicogenomic effects common to triazole antifungals and conserved between rats and humans. Toxicol Appl Pharmacol 238:80-89.
155. Gollamudi R, Gupta D, Goel S, Mani S. (2008). Novel orphan nuclear receptors-coregulator interactions controlling anti-cancer drug metabolism. Curr Drug Metab 9:611-613.
156. Gomez A, Karlgren M, Edler D, et al. (2007). Expression of CYP2W1 in colon tumors: Regulation by gene methylation. Pharmacogenomics 8: 1315-1325.
157. Gomez A, Nekvindova J, Travica S, et al. (2010). Colorectal cancer-specific cytochrome P450 2W1: Intracellular localization, glycosyla-tion, and catalytic activity. Mol Pharmacol 78:1004-1011.
158. Götz C, Pfeiffer R, Tigges J, et al. (2012a). Xenobiotic metabolism capacities of human skin in comparison with a 3D epidermis model and keratinocyte-based cell culture as in vitro alternatives for chemical testing: Activating enzymes (Phase I). Exp Dermatol 21: 358-363.
159. Götz C, Pfeiffer R, Tigges J, et al. (2012b). Xenobiotic metabolism capacities of human skin in comparison with a 3D-epidermis model and keratinocyte-based cell culture as in vitro alternatives for chemical testing: Phase II enzymes. Exp Dermatol 21: 364-369.
160. Gregory PA, Lewinsky RH, Gardner-Stephen DA, Mackenzie PI. (2004). Regulation of UDP glucuronosyltransferases in the gastrointestinal tract. Toxicol Appl Pharmacol 199:354-363.
161. Guengerich FP, Kim DH, Iwasaki M. (1991). Role of human cytochrome P450 IIE1 in the oxidation of many low molecular weight cancer suspects. Chem Res Toxicol 4:168-179.
162. Guengerich FP, Wu ZL, Bartleson CJ. (2005). Function of human cytochrome P450s: Characterization of the orphans. Biochem Biophys Res Commun 338:465-469.
163. Guidice JM, Marez D, Sabbagh N, et al. (1997). Evidence for CYP2D6 expression in human lung. Biochem Biophys Res Commun 241: 79-85.
164. Gumbleton M, Al-Jayyoussi G, Crandon-Lewis A, et al. (2011). Spatial expression and functionality of drug transporters in the intact lung: Objectives for further research. Adv Drug Deliv Rev 63: 110-118.
165. Gysler A, Kleuser B, Sippl W, et al. (1999). Skin penetration and metabolism of topical glucocorticoids in reconstructed epidermis and in excised human skin. Pharm Res 16:1386-1391.
166. Haag M, Fautrel A, Guillouzo A, et al. (2003). Expression of cytochromes P450 3A in mouse lung: Effects of dexamethasone and pregnenolone 16alpha-carbonitrile. Arch Toxicol 77:145-149.
167. Habano W, Gamo T, Sugai T, et al. (2009). CYP1B1, but not CYP1A1, is downregulated by promoter methylation in colorectal cancers. Int J Oncol 34:1085-1091.
168. Habano W, Gamo T, Terashima J, et al. (2011). Involvement of promoter methylation in the regulation of Pregnane X receptor in colon cancer cells. BMC Cancer 11:81.
169. Hanioka N, Oka H, Nagaoka K, et al. (2011). Effect of UDP-glucuronosyltransferase 2B15 polymorphism on bisphenol A glucur-onidation. Arch Toxicol 85:1373-1381.
170. Hediger MA, Clemencon B, Burrier RE, Bruford EA. (2013). The ABCs of membrane transporters in health and disease (SLC series): Introduction. Mol Aspects Med 34:95-107.
171. Hediger MA, Romero MF, Peng JB, et al. (2004). The ABCs of solute carriers: Physiological, pathological and therapeutic implications of human membrane transport proteins. Pflugers Arch 447: 465-468.
172. Hein DW, Doll MA, Rustan TD, et al. (1993). Metabolic activation and deactivation of arylamine carcinogens by recombinant human NAT1 and polymorphic NAT2 acetyltransferases. Carcinogenesis 14:1633-1638.
173. Hein DW. (2006). N-acetyltransferase 2 genetic polymorphism: Effects of carcinogen and haplotype on urinary bladder cancer risk. Oncogene 25:1649-1658.
174. Heise R, Mey J, Neis MM, et al. (2006). Skin retinoid concentrations are modulated by CYP26AI expression restricted to basal keratinocytes in normal human skin and differentiated 3D skin models. J Invest Dermatol 126:2473-2480.
175. Hellmold H, Overvik E, Strömstedt M, Gustafsson JA. (1993). Cytochrome P450 forms in the rodent lung involved in the metabolic activation of food-derived heterocyclic amines. Carcinogenesis 14: 1751-1757.
176. Her C, Kaur GP, Athwal RS, Weinshilboum RM. (1997). Human sulfotransferase SULT1C1: cDNA cloning, tissue-specific expression, and chromosomal localization. Genomics 41:467-470.
177. Herbst K, Föllmann W, Degen GH, Roos PH. (2010). Transcript-profiling for phase I and II-enzymes in 5637 urothelial cells: Basal expression pattern and modulation by xenobiotics. Naunyn-Schmiedeberg's Arch Pharmacol 381:61-62.
178. Herbst K, Roos PH. (2011). Synergistic effects of benzo[a]pyrene and aromatic amines on AhR-and NF-kB-signal transduction in urothelial cells. Toxicol Lett 205:S238-S239.
179. Hessel S, John A, Seidel A, Lampen A. (2013). Multidrug resistance-associated proteins are involved in the transport of the glutathione conjugates of the ultimate carcinogen of benzo[a]pyrene in human Caco-2 cells. Arch Toxicol 87:269-280.
180. Heydel JM, Holszytynska EJ, Legendre A, et al. (2010). UDP-glucuronosyltransferases (UGTs) in neuro-olfactory tissues: Expression, regulation, and function. Drug Metab Rev 42:74-97.
181. Hickman D, Pope J, Patil SD, et al. (1998). Expression of arylamine N-acetyltransferase in human intestine. Gut 42:402-409.
182. Hiley C, Bell J, Hume R, Strange R. (1989). Differential expression of alpha and pi isoenzymes of glutathione S-transferase in developing human kidney. Biochim Biophys Acta 990:321-324.
183. Hines RN. (2006). Developmental and tissue-specific expression of human flavin-containing monooxygenases 1 and 3. Expert Opin Drug Metab Toxicol 2:41-49.
184. Hoensch H, Peters WH, Roelofs HM, Kirch W. (2006). Expression of the glutathione enzyme system of human colon mucosa by localisation, gender and age. Curr Med Res Opin 22:1075-1083.
185. Hofmann C, Pütz C, Semder B, et al. (2006). Styrene-7, 8-oxide burden in ventilated, perfused lungs of mice and rats exposed to vaporous styrene. Toxicol Sci 90:39-48.
186. Hu JJ, Lee MJ, Vapiwala M, et al. (1993). Sex-related differences in mouse renal metabolism and toxicity of acetaminophen. Toxicol Appl Pharmacol 122:16-26.
187. Hu T, Bailey RE, Morrall SW, et al. (2009). Dermal penetration and metabolism of p-aminophenol and p-phenylenediamine: Application of the EpiDerm human reconstructed epidermis model. Toxicol Lett 188:119-129.
188. Hu T, Khambatta ZS, Hayden PJ, et al. (2010). Xenobiotic metabolism gene expression in the EpiDerm in vitro 3D human epidermis model compared to human skin. Toxicol In Vitro 24:1450-1463.
189. Husain A, Zhang X, Doll MA, et al. (2007). Identification of N-acetyltransferase 2 (NAT2) transcription start sites and quantitation of NAT2-specific mRNA in human tissues. Drug Metab Dispos 35: 721-727.
190. Ilett KF, Tee LB, Reeves PT, Minchin RF. (1990). Metabolism of drugs and other xenobiotics in the gut lumen and wall. Pharmacol Ther 46: 67-93.
191. Imaoka S, Yoneda Y, Matsuda T, et al. (1997). Mutagenic activation of urinary bladder carcinogens by CYP4B1 and the presence of CYP4B1 in bladder mucosa. Biochem Pharmacol 54:677-683.
192. Imaoka S, Yoneda Y, Sugimoto T, et al. (2000). CYP4B1 is a possible risk factor for bladder cancer in humans. Biochem Biophys Res Commun 277:776-780.
193. Ingelman-Sundberg M, Gomez A. (2010). The past, present and future of pharmacoepigenomics. Pharmacogenomics 11:625-627.
194. Ioannides C. (2013). Up-regulation of cytochrome P450 and phase II enzymes by xenobiotics in precision-cut tissue slices. Xenobiotica 43: 15-28
195. IPCS. (2005). Chemical specific adjustment factors for interspecies differences and human variability. Guidance document for use of data in dose/concentration-response assessment. Geneva: WHO.
196. Ishikawa T. (1992). The ATP-dependent glutathione S-conjugate export pump. Trends Biochem Sci 17:463-468.
197. Iwanari M, Nakajima M, Kizu R, et al. (2002). Induction of CYP1A1, CYP1A2, and CYP1B1 mRNAs by nitropolycyclic aromatic hydrocarbons in various human tissue-derived cells: Chemical-, cytochrome P450 isoform-, and cell-specific differences. Arch Toxicol 76:287-298.
198. Jackh C, Blatz V, Fabian E, et al. (2011). Characterization of enzyme activities of Cytochrome P450 enzymes, Flavin-dependent monoox-ygenases, N-acetyltransferases and UDP-glucuronyltransferases in human reconstructed epidermis and full-thickness skin models. Toxicol In Vitro 25:1209-1214.
199. Jackh C, Fabian E, van Ravenzwaay B, Landsiedel R. (2012). Relevance of xenobiotic enzymes in human skin in vitro models to activate pro-sensitizers. J Immunotoxicol 9:426-438.
200. Jaffe RL, Nicholson WJ, Garro AJ. (1983). Urinary mutagen levels in smokers. Cancer Lett 20:37-42.
201. Janmohamed A, Dolphin CT, Phillips IR, et al. (2001). Quantification and cellular localization of expression in human skin of genes encoding flavin-containing monooxygenases and cytochromes P450. Biochem Pharmacol 62:777-786.
202. Jedlitschky G, Cassidy AJ, Sales M, et al. (1999). Cloning and characterization of a novel human olfactory UDP-glucuronosyltrans-ferase. Biochem J 340:837-843.
203. Jennewein C, von Knethen A, Schmid T, et al. (2012). MicroRNA-27b contributes to lipopolysaccharide-mediated peroxisome proliferator-activated receptor gamma (PPARgamma) mRNA destabilization. J Biol Chem 285:11846-11853.
204. Jewell C, Prusakiewicz JJ, Ackermann C, et al. (2007). Hydrolysis of a series of parabens by skin microsomes and cytosol from human and minipigs and in whole skin in short-term culture. Toxicol Appl Pharmacol 225:221-228.
205. Jiang JG, Chen CL, Card JW, et al. (2005). Cytochrome P450 2J2 promotes the neoplastic phenotype of carcinoma cells and is up-regulated in human tumors. Cancer Res 65:4707-4715.
206. Jiang JG, Ning YG, Chen C, et al. (2007). Cytochrome p450 epoxygenase promotes human cancer metastasis. Cancer Res 67: 6665-6674.
207. Johansson I, Ingelman-Sundberg M. (2011). Genetic polymorphism and toxicology-with emphasis on cytochrome P450. Toxicol Sci 120: 1-13.
208. John A, Hessel S, Lampen A, Seidel A. (2012). Analysis of GSH conjugates of Bay-and Fjord-Region dihydrodiol epoxides of benzo[a]pyrene and dibenzo[a, l]pyrene and their transport in entero-cyte-like caco-2 cells. Polycyclic Aromatic Compounds 32:221-237.
209. Jugert FK, Agarwal R, Kuhn A, et al. (1994). Multiple cytochrome P450 isozymes in murine skin: Induction of P450 1A, 2B, 2E, and 3A by dexamethasone. J Invest Dermatol 102:970-975.
210. Juliano RL, Ling V. (1976). A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim Biophys Acta 455:152-162.
211. Kadlubar FF, Unruh LE, Flammang TJ, et al. (1981). Alteration of urinary levels of the carcinogen, N-hydroxy-2-naphthylamine, and its N-glucuronide in the rat by control of urinary pH, inhibition of metabolic sulfation, and changes in biliary excretion. Chem Biol Interact 33:129-147.
212. Kalmes M, Blomeke B. (2012). Impact of eugenol and isoeugenol on AhR translocation, target gene expression, and proliferation in human HaCaT keratinocytes. J Toxicol Environ Health A 75: 478-491.
213. Kalmes M, Hennen J, Clemens J, Blömeke B. (2011). Impact of aryl hydrocarbon receptor (AhR) knockdown on cell cycle progression in human HaCaT keratinocytes. Biol Chem 392:643-651.
214. Kalmes M, Neumeyer A, Rio P, et al. (2006). Impact of the arylhydrocarbon receptor on eugenol-and isoeugenol-induced cell cycle arrest in human immortalized keratinocytes (HaCaT). Biol Chem 387:1201-1207.
215. Kantola T, Kivisto KT, Neuvonen PJ. (1998). Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid. Clin Pharmacol Ther 63:397-402.
216. Kapitulnik J, Pelkonen O, Gundert-Remy U, et al. (2009). Effects of pharmaceuticals and other active chemicals at biological targets: Mechanisms, interactions, and integration into PB-PK/PD models. Expert Opin Ther Targets 13:867-887.
217. Karbiener M, Fischer C, Nowitsch S, et al. (2009). microRNA miR-27b impairs human adipocyte differentiation and targets PPARgamma. Biochem Biophys Res Commun 390:247-251.
218. Karlgren M, Backlund M, Johansson I, et al. (2004). Characterization and tissue distribution of a novel human cytochrome P450-CYP2U1. Biochem Biophys Res Commun 315:679-685.
219. Karlgren M, Gomez A, Stark K, et al. (2006). Tumor-specific expression of the novel cytochrome P450 enzyme, CYP2W1. Biochem Biophys Res Commun 341:451-458.
220. Karlgren M, Ingelman-Sundberg M. (2007). Tumour-specific expression of CYP2W1: Its potential as a drug target in cancer therapy. Expert Opin Ther Targets 11:61-67.
221. Karlgren M, Miura S, Ingelman-Sundberg M. (2005). Novel extrahepatic cytochrome P450s. Toxicol Appl Pharmacol 207:57-61.
222. Karschuk N, Tepe Y, Gerlach S, et al. (2010). A novel in vitro method for the detection and characterization of photosensitizers. PLoS One 5:e15221.
223. Katiyar SK, Matsui MS, Mukhtar H. (2000). Ultraviolet-B exposure of human skin induces cytochromes P450 1A1 and 1B1. J Invest Dermatol 114:328-333.
224. Kawakubo Y, Merk HF, Masaoudi TA, et al. (2000). N-Acetylation of paraphenylenediamine in human skin and keratinocytes. J Pharmacol Exp Ther 292:150-155.
225. Kawamura A, Westwood I, Wakefield L, et al. (2008). Mouse N-acetyltransferase type 2, the homologue of human N-acetyltransfer-ase type 1. Biochem Pharmacol 75:1550-1560.
226. Kearns GL, Abdel-Rahman SM, Alander SW, et al. (2003). Developmental pharmacology-Drug disposition, action, and therapy in infants and children. N Engl J Med 349:1157-1167.
227. Keeney DS, Skinner C, Travers JB, et al. (1998a). Differentiating keratinocytes express a novel cytochrome P450 enzyme, CYP2B19, having arachidonate monooxygenase activity. J Biol Chem 273: 32071-32079.
228. Keeney DS, Skinner C, Wei S, et al. (1998b). A keratinocyte-specific epoxygenase, CYP2B12, metabolizes arachidonic acid with unusual selectivity, producing a single major epoxyeicosatrienoic acid. J Biol Chem 273:9279-9284.
229. Keppler D. (2011). Multidrug resistance proteins (MRPs, ABCCs): Importance for pathophysiology and drug therapy. Handb Exp Pharmacol 201:299-323.
230. Khan AA, Chow EC, van Loenen-Weemaes AM, et al. (2009). Comparison of effects of VDR versus PXR, FXR and GR ligands on the regulation of CYP3A isozymes in rat and human intestine and liver. Eur J Pharm Sci 37:115-125.
231. Kietzmann D, Foth H, Geng WP, et al. (1995). Transpulmonary disposition of prilocaine, mepivacaine, and bupivacaine in humans in the course of epidural anaesthesia. Acta Anaesthesiol Scand 39: 885-890.
232. Kim RB, Wandel C, Leake B, et al. (1999). Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein. Pharm Res 16:408-414.
233. Kimura Y, Morita SY, Matsuo M, Ueda K. (2007). Mechanism of multidrug recognition by MDR1/ABCB1. Cancer Sci 98:1303-1310.
234. Kivistö KT, Griese EU, Stüven T, et al. (1997). Analysis of CYP2D6 expression in human lung: Implications for the association between CYP2D6 activity and susceptibility to lung cancer. Pharmacogenetics 7:295-302.
235. Klaassen CD, Aleksunes LM. (2010). Xenobiotic, bile acid, and cholesterol transporters: Function and regulation. Pharmacol Rev 62:1-96.
236. Klaassen CD, Lu H, Cui JY. (2011). Epigenetic regulation of drug processing genes. Toxicol Mech Methods 21:312-324.
237. Kliewer SA, Moore JT, Wade L, et al. (1998). An orphan nuclear receptor activated by pregnanes defines a novel steroid signaling pathway. Cell 92:73-82.
238. Ko K, Kurogi K, Davidson G, et al. (2012). Sulfation of ractopamine and salbutamol by the human cytosolic sulfotransferases. J Biochem 152: 275-283.
239. Koepsell H. (2013). The SLC22 family with transporters of organic cations, anions and zwitterions. Mol Aspects Med 34:413-435.
240. Koepsell H, Lips K, Volk C. (2007). Polyspecific organic cation transporters: Structure, function, physiological roles, and biopharma-ceutical implications. Pharm Res 24:1227-1251.
241. Kolars JC, Lown KS, Schmiedlin-Ren P, et al. (1994). CYP3A gene expression in human gut epithelium. Pharmacogenetics 4:247-259.
242. König J. (2011). Uptake transporters of the human OATP family: Molecular characteristics, substrates, their role in drug-drug interactions, and functional consequences of polymorphisms. Handb Exp Pharmacol 201:1-28.
243. König J, Müller F, Fromm MF. (2013). Transporters and drug-drug interactions: Important determinants of drug disposition and effects. Pharmacol Rev 5:944-966.
244. Kumarakulasingham M, Rooney PH, Dundas SR, et al. (2005). Cytochrome p450 profile of colorectal cancer: Identification of markers of prognosis. Clin Cancer Res 11:3758-3765.
245. Kurian P, Milo GE, Noyes I. (1992). Metabolism of benzo[a]pyrene in human skin xenografts. Cancer Biochem Biophys 13:23-31.
246. Lamba V, Panetta JC, Strom S, Schuetz EG. (2010). Genetic predictors of interindividual variability in hepatic CYP3A4 expression. J Pharmacol Exp Ther 332:1088-1099.
247. Lamba V, Yasuda K, Lamba JK, et al. (2004). PXR (NR1I2): Splice variants in human tissues, including brain, and identification of neurosteroids and nicotine as PXR activators. Toxicol Appl Pharmacol 199:251-265.
248. Lash LH, Elfarra AA, Anders MW. (1986). Renal cysteine conjugate beta-lyase. Bioactivation of nephrotoxic cysteine S-conjugates in mitochondrial outer membrane. J Biol Chem 261:5930-5935.
249. Lash LH, Putt DA, Cai H. (2008). Drug metabolism enzyme expression and activity in primary cultures of human proximal tubular cells. Toxicology 244:56-65.
250. Lau YY, Wu CY, Okochi H, Benet LZ. (2004). Ex situ inhibition of hepatic uptake and efflux significantly changes metabolism: Hepatic enzyme-transporter interplay. J Pharmacol Exp Ther 308: 1040-1045.
251. Lee CA, Neul D, Clouser-Roche A, et al. (2010). Identification of novel substrates for human cytochrome P450 2J2. Drug Metab Dispos 38: 347-356.
252. Leslie EM, Deeley RG, Cole SP. (2005). Multidrug resistance proteins: Role of P-glycoprotein, MRP1, MRP2, and BCRP (ABCG2) in tissue defense. Toxicol Appl Pharmacol 204:216-237.
253. Li Q, Csanády GA, Kessler W, et al. (2011a). Kinetics of ethylene and ethylene oxide in subcellular fractions of lungs and livers of male B6C3F1 mice and male Fischer 344 rats and of human livers. Toxicol Sci 123:384-398.
254. Li X, Hu Z, Qu X, et al. (2011b). Putative EPHX1 enzyme activity is related with risk of lung and upper aerodigestive tract cancers: A comprehensive meta-analysis. PLoS One 6:e14749.
255. Li Y, Lu J, Paxton JW. (2012). The role of ABC and SLC transporters in the pharmacokinetics of dietary and herbal phyto-chemicals and their interactions with xenobiotics. Curr Drug Metab 13:624-639.
256. Lichter J, Heckelen A, Fischer K, Blomeke B. (2008). Expression of N-acetyltransferase in monocyte-derived dendritic cells. J Toxicol Environ Health A 71:960-964.
257. Lin JH, Chiba M, Baillie TA. (1999). Is the role of the small intestine in first-pass metabolism overemphasized? Pharmacol Rev 51:135-158.
258. Lock EA, Reed CJ. (1998). Xenobiotic metabolizing enzymes of the kidney. Toxicol Pathol 26:18-25.
259. Loehle JA, Cornish V, Wakefield L, et al. (2006). N-acetyltransferase (Nat) 1 and 2 expression in Nat2 knockout mice. J Pharmacol Exp Ther 319:724-728.
260. Lohr JW, Willsky GR, Acara MA. (1998). Renal drug metabolism. Pharmacol Rev 50:107-141.
261. Lown KS, Bailey DG, Fontana RJ, et al. (1997). Grapefruit juice increases felodipine oral availability in humans by decreasing intestinal CYP3A protein expression. J Clin Invest 99:2545-2553.
262. Lutz W, Tarkowski M, Nowakowska E. (2001). Genetic polymorphism of glutathione s-transferase as a factor predisposing to allergic dermatitis. Med Pr 52:45-51.
263. Luu-The V, Duche D, Ferraris C, et al. (2009). Expression profiles of phases 1 and 2 metabolizing enzymes in human skin and the reconstructed skin models Episkin(TM) and full thickness model from Episkin(TM). J Steroid Biochem Mol Biol 116:178-186.
264. Ma L, Sun J, Peng Y, et al. (2012a). Glucuronidation of edaravone by human liver and kidney microsomes: Biphasic kinetics and identification of UGT1A9 as the major UDP-glucuronosyltransferase isoform. Drug Metab Dispos 40:734-741.
265. Ma R, Gu Y, Zhao S, et al. (2012b). Expressions of vitamin D metabolic components VDBP, CYP2R1, CYP27B1, CYP24A1, and VDR in placentas from normal and preeclamptic pregnancies. Am J Physiol Endocrinol Metab 303:E928-E935.
266. Macé K, Bowman ED, Vautravers P, et al. (1998). Characterisation of Xenobiotic-metabolising enzyme expression in human bronchial mucosa and peripheral lung tissues. Eur J Cancer 34:914-920.
267. Madanayake TW, Fidler TP, Fresquez TM, et al. (2012). Cytochrome P450 2S1 depletion enhances cell proliferation and migration in bronchial epithelial cells, in part, through modulation of prostaglandin E(2) synthesis. Drug Metab Dispos 40:2119-2125.
268. Martone T, Airoldi L, Magagnotti C, et al. (1998). 4-Aminobiphenyl-DNA adducts and p53 mutations in bladder cancer. Int J Cancer 75: 512-516.
269. Mastrangelo G, Fadda E, Marzia V. (1996). Polycyclic aromatic hydrocarbons and cancer in man. Environ Health Perspect 104: 1166-1170.
270. Matic M, Mahns A, Tsoli M, et al. (2007). Pregnane X receptor: Promiscuous regulator of detoxification pathways. Int J Biochem Cell Biol 39:478-483.
271. Matic M, Simic T, Dragicevic D, et al. (2010). Isoenzyme profile of glutathione transferases in transitional cell carcinoma of upper urinary tract. Transl Res 155:256-262.
272. McDonnell WM, Scheiman JM, Traber PG. (1992). Induction of cytochrome P450IA genes (CYP1A) by omeprazole in the human alimentary tract. Gastroenterology 103:1509-1516.
273. McGurk KA, Brierley CH, Burchell B. (1998). Drug glucuronidation by human renal UDP-glucuronosyltransferases. Biochem Pharmacol 55: 1005-1012.
274. McKay JA, Weaver RJ, Murray GI, et al. (1995). Localization of microsomal epoxide hydrolase in normal and neoplastic human kidney. J Histochem Cytochem 43:615-620.
275. McKinnon RA, Burgess WM, Hall PM, et al. (1995). Characterisation of CYP3A gene subfamily expression in human gastrointestinal tissues. Gut 36:259-267.
276. McKinnon RA, McManus ME. (1996). Localization of cytochromes P450 in human tissues: Implications for chemical toxicity. Pathology 28:148-155.
277. Medhora MJ, Mundey Daniels K, Fisslthaler B, et al. (2003). Epoxygenase-driven angiogenesis in human lung microvascular endothelial cells. Am J Physiol Heart Circ Physiol 284:H215-H224.
278. Meinl W, Ebert B, Glatt H, Lampen A. (2008). Sulfotransferase forms expressed in human intestinal Caco-2 and TC7 cells at varying stages of differentiation and role in benzo[a]pyrene metabolism. Drug Metab Dispos 36:276-283.
279. Meinl W, Pabel U, Osterloh-Quiroz M, et al. (2006). Human sulphotransferases are involved in the activation of aristolochic acids and are expressed in renal target tissue. Int J Cancer 118: 1090-1097.
280. Miki Y, Suzuki T, Tazawa C, et al. (2005). Steroid and xenobiotic receptor (SXR), cytochrome P450 3A4 and multidrug resistance gene 1 in human adult and fetal tissues. Mol Cell Endocrinol 231: 75-85.
281. Miyagi SJ, Collier AC. (2011). The development of UDP-glucuronosyl- transferases 1A1 and 1A6 in the pediatric liver. Drug Metab Dispos 39:912-919.
282. Mohri T, Nakajima M, Fukami T, et al. (2010). Human CYP2E1 is regulated by miR-378. Biochem Pharmacol 79:1045-1052.
283. Morel F, Rauch C, Petit E. (2004). Gene and protein characterization of the human glutathione S-transferase kappa and evidence for a peroxisomal localization. J Biol Chem 279:16246-16253.
284. Morgan ET, Goralski KB, Piquette-Miller M, et al. (2008). Regulation of drug-metabolizing enzymes and transporters in infection, inflammation, and cancer. Drug Metab Dispos 36:205-216.
285. Motika MS, Zhang J, Ralph EC, et al. (2012). pH dependence on functional activity of human and mouse flavin-containing monoox-ygenase 5. Biochem Pharmacol 83:962-968.
286. Mukherjee S, Chaudhuri K. (2011). NQO1 C 609 T polymorphisms analyzed in a population from Kolkata, West Bengal. Indian J Hum Genet 17:244-245.
287. Mukhtar H, Bickers DR. (1981). Drug metabolism in skin. Comparative activity of the mixed-function oxidases, epoxide hydratase, and glutathione S-transferase in liver and skin of the neonatal rat. Drug Metab Dispos 9:311-314.
288. Mukhtar H, Merk HF, Athar M. (1989). Skin chemical carcinogenesis. Clin Dermatol 7:1-10.
289. Münzel PA, Schmohl S, Heel H, et al. (1999). Induction of human UDP glucuronosyltransferases (UGT1A6, UGT1A9, and UGT2B7) by t-butylhydroquinone and 2, 3, 7, 8-tetrachlorodibenzo-p-dioxin in Caco-2 cells. Drug Metab Dispos 27:569-573.
290. Müller F, Fromm MF. (2011). Transporter-mediated drug-drug interactions. Pharmacogenomics 12:1017-1037.
291. Murakami T, Takano M. (2008). Intestinal efflux transporters and drug absorption. Expert Opin Drug Metab Toxicol 4:923-939.
292. Murray GI, Taylor MC, McFadyen MC, et al. (1997). Tumor-specific expression of cytochrome P450 CYP1B1. Cancer Res 57: 3026-3031.
293. Murray GI, Taylor VE, McKay JA, et al. (1995). Expression of xenobiotic metabolizing enzymes in tumours of the urinary bladder. Int J Exp Pathol 76:271-276.
294. Nakajima M, Itoh M, Sakai H, et al. (2006). CYP2A13 expressed in human bladder metabolically activates 4-aminobiphenyl. Int J Cancer 119:2520-2526.
295. Nakamura A, Nakajima M, Yamanaka H, et al. (2008a). Expression of UGT1A and UGT2B mRNA in human normal tissues and various cell lines. Drug Metab Dispos 36:1461-1464.
296. Nakamura T, Yamamori M, Sakaeda T. (2008b). Pharmacogenetics of intestinal absorption. Curr Drug Deliv 5:153-169.
297. Nakayama K, Nitto T, Inoue T, et al. (2008). Expression of the cytochrome P450 epoxygenase CYP2J2 in human monocytic leukocytes. Life Sci 83:339-345.
298. Neis MM, Wendel A, Wiederholt T, et al. (2010). Expression and induction of cytochrome p450 isoenzymes in human skin equivalents. Skin Pharmacol Physiol 23:29-39.
299. Nelson SD, Trager WF. (2003). The use of deuterium isotope effects to probe the active site properties, mechanism of cytochrome P450-catalyzed reactions, and mechanisms of metabolically dependent toxicity. Drug Metab Dispos 31:1481-1498.
300. Nem D, Baranyai D, Qiu H, et al. (2012). Pregnane X receptor and yin yang 1 contribute to the differential tissue expression and induction of CYP3A5 and CYP3A4. PLoS One 7:e30895.
301. Newman JW, Morisseau C, Hammock BD. (2005). Epoxide hydrolases: Their roles and interactions with lipid metabolism. Prog Lipid Res 44: 1-51.
302. Nies AT, Damme K, Schaeffeler E, Schwab M. (2012). Multidrug and toxin extrusion proteins as transporters of antimicrobial drugs. Expert Opin Drug Metab Toxicol 8:1565-1577.
303. Niestroy J, Barbara A, Herbst K, et al. (2011). Single and concerted effects of benzo[a]pyrene and flavonoids on the AhR and Nrf2-pathway in the human colon carcinoma cell line Caco-2. Toxicol In Vitro 25:671-683.
304. Nishida CR, Lee M, de Montellano PR. (2010). Efficient hypoxic activation of the anticancer agent AQ4N by CYP2S1 and CYP2W1. Mol Pharmacol 78:497-502.
305. Nishimura M, Naito S, Yokoi T. (2004). Tissue-specific mRNA expression profiles of human nuclear receptor subfamilies. Drug Metab Pharmacokinet 19:135-149.
306. Nishimura M, Naito S. (2006). Tissue-specific mRNA expression profiles of human phase I metabolizing enzymes except for cyto-chrome P450 and phase II metabolizing enzymes. Drug Metab Pharmacokinet 21:357-374.
307. Nishimura M, Yaguti H, Yoshitsugu H, et al. (2003). Tissue distribution of mRNA expression of human cytochrome P450 isoforms assessed by high-sensitivity real-time reverse transcription PCR. Yakugaku Zasshi 123:369-375.
308. Nohynek GJ, Duche D, Garrigues A, et al. (2005). Under the skin: Biotransformation of para-aminophenol and para-phenylenediamine in reconstructed human epidermis and human hepatocytes. Toxicol Lett 158:186-212.
309. Norden G. (1953). The rate of appearance, metabolism and disappearance of 3, 4-benzpyrene in the epithelium of mouse skin after a single application in a volatile solvent. Acta Pathol Microbiol Scand Suppl 96:1-100.
310. Oda S, Nakajima M, Hatakeyama M, et al. (2012a). Preparation of a specific monoclonal antibody against human UDP-glucuronosyltrans-ferase (UGT) 1A9 and evaluation of UGT1A9 protein levels in human tissues. Drug Metab Dispos 40:1620-1627.
311. Oda Y, Nakajima M, Mohri T, et al. (2012b). Aryl hydrocarbon receptor nuclear translocator in human liver is regulated by miR-24. Toxicol Appl Pharmacol 260:222-231.
312. Oesch F, Arand M. (1999). Xenobiotic metabolism. In: Marquardt H, Schäfer S, McLellan D, Welsch C, eds. Toxicology. San Diego: Academic Press, 83-110.
313. Oesch F, Glatt H, Schmassmann H. (1977a). The apparent ubiquity of epoxide hydratase in rat organs. Biochem Pharmacol 26:603-607.
314. Oesch F, Raphael D, Schwind H, Glatt HR. (1977b). Species differences in activating and inactivating enzymes related to the control of mutagenic metabolites. Arch Toxicol 39:97-108.
315. Oesch F, Fabian E, Oesch-Bartlomowicz B, et al. (2007). Drug-metabolizing enzymes in the skin of man, rat, and pig. Drug Metab Rev 39:659-698.
316. Oesch-Bartlomowicz B, Oesch F. (2007). Mechanisms of toxication and detoxication which challenge drug candidates and drugs. In: Triggle D, Taylor J, eds. Comprehensive medicinal medicine. Philadelphia (PA): Elsevier, 193-214.
317. Ohno S, Nakajin S. (2009). Determination of mRNA expression of human UDP-glucuronosyltransferases and application for localization in various human tissues by real-time reverse transcriptase-polymer-ase chain reaction. Drug Metab Dispos 37:32-40.
318. Ohno S, Nakajin S. (2011). Quantitative analysis of UGT2B28 mRNA expression by real-time RT-PCR and application to human tissue distribution study. Drug Metab Lett 5:202-208.
319. Ott H, Bergström MA, Heise R, et al. (2009). Cutaneous metabolic activation of carvoxime, a self-activating, skin-sensitizing prohapten. Chem Res Toxicol 22:399-405.
320. Ou Z, Wada T, Gramignoli R, et al. (2011). MicroRNA hsa-miR-613 targets the human LXRa gene and mediates a feedback loop of LXRa autoregulation. Mol Endocrinol 25:584-596.
321. Pacifici GM, Bencini C, Rane A. (1986). Acetyltransferase in humans: Development and tissue distribution. Pharmacology 32:283-291.
322. Pacifici GM, Franchi M, Bencini C, et al. (1988a). Tissue distribution of drug-metabolizing enzymes in humans. Xenobiotica 18:849-856.
323. Pacifici GM, Mogavero S, Giuliani L, Rane A. (1991a). Conjugation of benzoic acid with glycine in the human fetal and adult liver and kidney. Dev Pharmacol Ther 17:52-62.
324. Pacifici GM, Temellini A, Giuliani L, et al. (1988b). Cytosolic epoxide hydrolase in humans: Development and tissue distribution. Arch Toxicol 62:254-257.
325. Pacifici GM, Vannucci L, Bencini C, et al. (1991b). Sulphation of hydroxybiphenyls in human tissues. Xenobiotica 21:1113-1118.
326. Paine MF, Hart HL, Ludington SS, et al. (2006). The human intestinal cytochrome P450 "pie". Drug Metab Dispos 34:880-886.
327. Pan YZ, Gao W, Yu AM. (2009). MicroRNAs regulate CYP3A4 expression via direct and indirect targeting. Drug Metab Dispos 37: 2112-2117.
328. Partosch F, Mielke H, Gundert-Remy U. (2013). Functional UDP-glucuronyltransferase 2B15 polymorphism and bisphenol A concentrations in blood: Results from physiologically based kinetic modelling. Arch Toxicol 87:1257-1264.
329. Pavek P, Cerveny L, Svecova L, et al. (2007). Examination of Glucocorticoid receptor alpha-mediated transcriptional regulation of P-glycoprotein, CYP3A4, and CYP2C9 genes in placental trophoblast cell lines. Placenta 28:1004-1011.
330. Pavek P, Dvorak Z. (2007). Xenobiotic-induced transcriptional regulation of xenobiotic metabolizing enzymes of the cytochrome P450 super-family in human extrahepatic tissues. Curr Drug Metab 9:129-143.
331. Pavek P, Merino G, Wagenaar E, et al. (2005). Human breast cancer resistance protein: Interactions with steroid drugs, hormones, the dietary carcinogen 2-amino-1-methyl-6-phenylimidazo(4, 5-b)pyri-dine, and transport of cimetidine. J Pharmacol Exp Ther 312:144-152.
332. Peiser M, Wanner R, Kolde G. (2004). Human epidermal Langerhans cells differ from monocyte-derived Langerhans cells in CD80 expression and in secretion of IL-12 after CD40 cross-linking. Leukoc Biol 76:616-622.
333. Pelkonen O, Kapitulnik J, Gundert-Remy U, et al. (2008). Local kinetics and dynamics of xenobiotics. Crit Rev Toxicol 38:697-720.
334. Peters WH, Allebes WA, Jansen PL, et al. (1987). Characterization and tissue specificity of a monoclonal antibody against human uridine 5-diphosphate-glucuronosyltransferase. Gastroenterology 93:162-169.
335. Peters WH, Kock L, Nagengast FM, Kremers PG. (1991). Biotransformation enzymes in human intestine: Critical low levels in the colon? Gut 32:408-412.
336. Petzinger E, Geyer J. (2006). Drug transporters in pharmacokinetics. Naunyn Schmiedebergs Arch Pharmacol 372:465-75.
337. Piao MS, Park JJ, Choi JY, et al. (2012). Nrf2-dependent and Nrf2-independent induction of phase 2 detoxifying and antioxidant enzymes during keratinocyte differentiation. Arch Dermatol Res 304:387-395.
338. Pot LM, Alizadeh BZ, Ahrenberg D, et al. (2011). No major role for glutathione S-transferase gene polymorphisms in sensitization to para-phenylenediamine and other xenobiotics: A study of association and a meta-analysis. Br J Dermatol 164:890-892.
339. Pot LM, Scheitza S, Coenraads PJ, Blömeke B. (2013). Penetration and haptenation of p-phenylenediamine. Contact Dermatitis 68:193-207.
340. Python F, Goebel C, Aeby P. (2007). Assessment of the U937 cell line for the detection of contact allergens. Toxicol Appl Pharmacol 220:113-124.
341. Rae JM, Johnson MD, Lippman ME, Flockhart DA. (2001). Rifampin is a selective, pleiotropic inducer of drug metabolism genes in human hepatocytes: Studies with cDNA and oligonucleotide expression arrays. J Pharmacol Exp Ther 299:849-857.
342. Raghavan D, Burgess E, Gaston KE, et al. (2012). Neoadjuvant and adjuvant chemotherapy approaches for invasive bladder cancer. Semin Oncol 39:588-597.
343. Raijmakers MT, Steegers EA, Peters WH. (2001). Glutathione S-transferases and thiol concentrations in embryonic and early fetal tissues. Hum Reprod 16:2445-2450.
344. Raunio H, Hakkola J, Hukkanen J, et al. (1999). Expression of xenobiotic-metabolizing CYPs in human pulmonary tissue. Exp Toxicol Pathol 51:412-417.
345. Raza H, Awasthi YC, Zaim MT, et al. (1991). Glutathione S-transferases in human and rodent skin: Multiple forms and species-specific expression. J Invest Dermatol 96:463-467.
346. 2+ concentration. Proc Natl Acad Sci USA 87:1825-1829.
347. Ren Q, Paulsen IT. (2005). Comparative analyses of fundamental differences in membrane transport capabilities in prokaryotes and eukaryotes. PLoS Comput Biol 1:e27.
348. Renaud HJ, Cui JY, Khan M, Klaassen CD. (2011). Tissue distribution and gender-divergent expression of 78 cytochrome P450 mRNAs in mice. Toxicol Sci 124:261-277.
349. Riches Z, Stanley EL, Bloomer JC, Coughtrie MW. (2009). Quantitative evaluation of the expression and activity of five major sulfotrans-ferases (SULTs) in human tissues: The SULT "pie". Drug Metab Dispos 37:2255-2261.
350. Riedel K, Scherer G, Engl J, et al. (2006). Determination of three carcinogenic aromatic amines in urine of smokers and nonsmokers. J Anal Toxicol 30:187-195.
351. Rieger JK, Klein K, Winter S, Zanger UM. (2013). Expression variability of ADME-related microRNAs in human liver: Influence of non-genetic factors and association with gene expression. Drug Metab Dispos 41:1752-1762.
352. Rivera SP, Saarikoski ST, Hankinson O. (2002). Identification of a novel dioxin-inducible cytochrome P450. Mol Pharmacol 61:255-259.
353. Robertson IG, Guthenberg C, Mannervik B, Jernström B. (1986). Differences in stereoselectivity and catalytic efficiency of three human glutathione transferases in the conjugation of glutathione with 7 beta, 8 alpha-dihydroxy-9 alpha, 10 alpha-oxy-7, 8, 9, 10-tetrahydrobenzo(a)pyrene. Cancer Res 46:2220-2224.
354. Rodilla V, Benzie AA, Veitch JM, et al. (1998). Glutathione S-transferases in human renal cortex and neoplastic tissue: enzymatic activity, isoenzyme profile and immunohistochemical localization. Xenobiotica 28:443-456.
355. Rolsted K, Kissmeyer AM, Rist GM, et al. (2008). Evaluation of cytochrome P450 activity in vitro, using dermal and hepatic microsomes from four species and two keratinocyte cell lines in culture. Arch Dermatol Res 300:11-18.
356. Roos PH, Ashoff J. (2011). Expression of cytochromes P450, phase II enzymes, signalling components and tumor markers in human urothelial cell lines. Naunyn-Schmiedeberg's Arch Pharmacol 383: 93-94.
357. Roos PH, Belik R, Föllmann W, et al. (2006a). Expression of cytochrome P450 enzymes CYP1A1, CYP1B1, CYP2E1 and CYP4B1 in cultured transitional cells from specimens of the human urinary tract and from urinary sediments. Arch Toxicol 80:45-52.
358. Roos PH, Bolt HM. (2005). Cytochrome P450 interactions in human cancers: New aspects considering CYP1B1. Expert Opin Drug Metab Toxicol 1:187-202.
359. Roos PH, Dörrenhaus A, Roth G, et al. (2006b). CYP4B1 expression in urothelial cells, polymorphism and bladder cancer. Naunyn-Schmiedeberg's Arch Pharmacol 372:131-132.
360. Rosenberg DW, Leff T. (1993). Regulation of cytochrome P450 in cultured
361. Rothman N, Bhatnagar VK, Hayes RB, et al. (1996). The impact of interindividual variation in NAT2 activity on benzidine urinary metabolites and urothelial DNA adducts in exposed workers. Proc Natl Acad Sci USA 93:5084-5089.
362. Rowland A, Miners JO, Mackenzie PI. (2013). The UDP-glucuronosyl- transferases: Their role in drug metabolism and detoxification. Int J Biochem Cell Biol 45:1121-1132.
363. Rush GF, Smith JH, Newton JF, Hook JB. (1984). Chemically induced nephrotoxicity: Role of metabolic activation. Crit Rev Toxicol 13: 99-160.
364. Rylander T, Neve EP, Ingelman-Sundberg M, Oscarson M. (2001). Identification and tissue distribution of the novel human cytochrome P450 2S1 (CYP2S1). Biochem Biophys Res Commun 281:529-535.
365. Saarikoski ST, Rivera SP, Hankinson O, Husgafvel-Pursiainen K. (2005a). CYP2S1: A short review. Toxicol Appl Pharmacol 207:62-69.
366. Saarikoski ST, Wikman HA, Smith G, et al. (2005b). Localization of cytochrome P450 CYP2S1 expression in human tissues by in situ hybridization and immunohistochemistry. J Histochem Cytochem 53: 549-556.
367. Saeki M, Saito Y, Nagano M, et al. (2002). mRNA expression of multiple cytochrome p450 isozymes in four types of cultured skin cells. Int Arch Allergy Immunol 127:333-336.
368. Saier Jr MH, Yen MR, Noto K, et al. (2009). The Transporter Classification Database: Recent advances. Nucleic Acids Res 37: D274-D278.
369. Saip R, Sen F, Vural B, et al. (2011). Glutathione S-transferase P1 polymorphisms are associated with time to tumor progression in small cell lung cancer patients. J BUON 16:241-246.
370. Sakukawa R, Murakami K, Ikeda T, et al. (1998). Effect of 4-[3, 5-bis(trimethylsilyl)benzamido] benzoic acid (TAC-101) on the liver metastasis of colon 26-L5 carcinoma cells. Oncol Res 10:287-293.
371. Saleem MM, Al-Tamer YY, Skursky L, Al-Habbal Z. (1984). Alcohol dehydrogenase activity in the human tissues. Biochem Med 31:1-9.
372. Salinas AE, Wong MG. (1999). Glutathione S-transferases A review. Curr Med Chem 6:279-309.
373. Saurat JH, Kaya G, Saxer-Sekulic N, et al. (2012). The cutaneous lesions of dioxin exposure: Lessons from the poisoning of Victor Yushchenko. Toxicol Sci 125:310-317.
374. Scarborough PE, Ma J, Qu W, Zeldin DC. (1999). P450 subfamily CYP2J and their role in the bioactivation of arachidonic acid in extrahepatic tissues. Drug Metab Rev 31:205-234.
375. Scharmach E, Hessel S, Niemann B, Lampen A. (2009). Glutathione S-transferase expression and isoenzyme composition during cell differentiation of Caco-2 cells. Toxicology 265:122-126.
376. Schladt L, Wörner W, Setiabudi F, Oesch F. (1986). Distribution and inducibility of cytosolic epoxide hydrolase in male Sprague-Dawley rats. Biochem Pharmacol 35:3309-3316.
377. Schnuch A, Westphal G, Mössner R, et al. (2011). Genetic factors in contact allergy Review and future goals. Contact Dermatitis 64:2-23.
378. Schuetz EG, Beck WT, Schuetz JD. (1996). Modulators and substrates of P-glycoprotein and cytochrome P4503A coordinately up-regulate these proteins in human colon carcinoma cells. Mol Pharmacol 49: 311-318.
379. Schumann CA, Dörrenhaus A, Franzke J, et al. (2008). Concomitant dection of CYP1A1 enzymatic activity and CYP1A1 protein in individual cells of a human urothelial cell line using a bilayer microfluidic device. Anal Bioanal Chem 392:1159-1166.
380. Seliskar M, Rozman D. (2007). Mammalian cytochromes P450 Importance of tissue specificity. Biochim Biophys Acta 1770:458-466.
381. Sevanian A, Stein RA, Mead JF. (1980). Lipid epoxide hydrolase in rat lung preparations. Biochim Biophys Acta 614:489-500.
382. Sevior DK, Hokkanen J, Tolonen A, et al. (2010). Rapid screening of commercially available herbal products for the inhibition of major human hepatic cytochrome P450 enzymes using the N-in-one cocktail. Xenobiotica 40:245-254.
383. Shawahna R, Uchida Y, DeclOves X, et al. (2011). Transcriptomic and quantitative proteomic analysis of transporters and drug metabolizing enzymes in freshly isolated human brain microvessels. Mol Pharm 8:1332-1341.
384. Shen S, Zhang W. (2010). ABC transporters and drug efflux at the blood-brain barrier. Rev Neurosci 21:29-53.
385. Sheweita SA, Abu El-Maati MR, El-Shahat FG, Bazeed MA. (2001). Changes in the expression of cytochrome P450 2E1 and the activity of carcinogen- metabolizing enzymes in Schistosoma haematobium-infected human bladder tissues. Toxicology 162:43-52.
386. Shimada T, Martin MV, Pruess-Schwartz D, et al. (1989). Roles of individual human cytochrome P-450 enzymes in the bioactivation of benzo(a)pyrene, 7, 8-dihydroxy-7, 8-dihydrobenzo(a)pyrene, and other dihydrodiol derivatives of polycyclic aromatic hydrocarbons. Cancer Res 49:6304-6312.
387. Shimada T, Oda Y, Gillam EM, et al. (2001). Metabolic activation of polycyclic aromatic hydrocarbons and other procarcinogens by cytochromes P450 1A1 and P450 1B1 allelic variants and other human cytochromes P450 in Salmonella typhimurium NM2009. Drug Metab Dispos 29:1176-1182.
388. Shimada T, Sugie A, Shindo M, et al. (2003). Tissue-specific induction of cytochromes P450 1A1 and 1B1 by polycyclic aromatic hydrocarbons and polychlorinated biphenyls in engineered C57BL/6J mice of arylhydrocarbon receptor gene. Toxicol Appl Pharmacol 187:1-10.
389. Shitara Y, Sugiyama Y. (2006). Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors: Drug-drug interactions and interindividual differences in transporter and metabolic enzyme functions. Pharmacol Ther 112:71-105.
390. Sieben S, Baron JM, Blömeke B, Merk HF. (1999). Multiple cytochrome P450-isoenzymes mRNA are expressed in dendritic cells. Int Arch Allergy Immunol 118:358-361.
391. Sieben S, Kawakubo Y, Sachs B, et al. (2001). T cell responses to paraphenylenediamine and to its metabolites mono-and diacetyl- paraphenylenediamine. Int Arch Allergy Immunol 124:356-358.
392. Siissalo S, Zhang H, Stilgenbauer E, et al. (2008). The expression of most UDP-glucuronosyltransferases (UGTs) is increased significantly during Caco-2 cell differentiation, whereas UGT1A6 is highly expressed also in undifferentiated cells. Drug Metab Dispos 36: 2331-2336.
393. Simic T, Savic-Radojevic A, Pljesa-Ercegovac M, et al. (2009). Glutathione S-transferases in kidney and urinary bladder tumors. Nat Rev Urol 6:281-289.
394. Singh SV, Roberts B, Gudi VA, et al. (1991). Immunohistochemical localization, purification, and characterization of human urinary bladder glutathione S-transferases. Biochim Biophys Acta 1074: 363-370.
395. Smith BJ, Curtis JF, Eling TE. (1991). Bioactivation of xenobiotics by prostaglandin H synthase. Chem Biol Interact 79:245-264.
396. Smith CK, Cheung C, Elahi EN, Hotchkiss SA. (2001). High-performance liquid chromatography method for the quantification of non-radiolabelled cinnamic compounds in analytes derived from human skin absorption and metabolism experiments. J Chromatogr B Biomed Sci Appl 758:249-264.
397. Smith CK, Moore CA, Elahi EN, et al. (2000). Human skin absorption and metabolism of the contact allergens, cinnamic aldehyde, and cinnamic alcohol. Toxicol Appl Pharmacol 168:189-199.
398. Smith G, Wolf CR, Deeni YY, et al. (2003). Cutaneous expression of cytochrome P450 CYP2S1: Individuality in regulation by therapeutic agents for psoriasis and other skin diseases. Lancet 361: 1336-1343.
399. Sohlenius-Sternbeck AK, Orzechowski A. (2004). Characterization of the rates of testosterone metabolism to various products and of glutathione transferase and sulfotransferase activities in rat intestine and comparison to the corresponding hepatic and renal drug-metabolizing enzymes. Chem Biol Interact 148: 49-56.
400. Song DK, Xing DL, Zhang LR, et al. (2009). Association of NAT2, GSTM1, GSTT1, CYP2A6, and CYP2A13 gene polymorphisms with susceptibility and clinicopathologic characteristics of bladder cancer in Central China. Cancer Detect Prev 32:416-423.
401. Speerschneider P, Dekant W. (1995). Renal tumorigenicity of 1, 1-dichloroethene in mice: the role of male-specific expression of cytochrome P450 2E1 in the renal bioactivation of 1, 1-dichloroethene. Toxicol Appl Pharmacol 130:48-56.
402. Sreeja L, Syamala V, Hariharan S, et al. (2008). Glutathione S-transferase M1, T1 and P1 polymorphisms: Susceptibility and outcome in lung cancer patients. J Exp Ther Oncol 7:73-85.
403. Stanley EL, Hume R, Coughtrie MW. (2005). Expression profiling of human fetal cytosolic sulfotransferases involved in steroid and thyroid hormone metabolism and in detoxification. Mol Cell Endocrinol 240: 32-42.
404. Stanley LA, Coroneos E, Cuff R, et al. (1996). Immunochemical detection of arylamine N-acetyltransferase in normal and neoplastic bladder. J Histochem Cytochem 44:1059-1067.
405. Stanley LA, Mills IG, Sim E. (1997). Localization of polymorphic N-acetyltransferase (NAT2) in tissues of inbred mice. Pharmacogenetics 7:121-130.
406. Stewart LV, Thomas ML. (1997). Retinoids differentially regulate the proliferation of colon cancer cell lines. Exp Cell Res 233:321-329.
407. Strassburg CP, Kneip S, Topp J, et al. (1999a). Polymorphic gene regulation and interindividual variation of UDP-glucuronosyltransferase activity in human small intestine. J Biol Chem 275:36164-36171.
408. Strassburg CP, Nguyen N, Manns MP, Tukey RH. (1999b). UDP-glucuronosyltransferase activity in human liver and colon. Gastroenterology 116:149-160.
409. Su T, Bao Z, Zhang QY, et al. (2000). Human cytochrome P450 CYP2A13: Predominant expression in the respiratory tract and its high efficiency metabolic activation of a tobacco-specific carcinogen, 4-(methylnitrosamino)-1- (3-pyridyl)-1-butanone. Cancer Res 60: 5074-5079.
410. Surh YJ, Lai CC, Miller JA, Miller EC. (1987). Hepatic DNA and RNA adduct formation from the carcinogen 7-hydroxymethyl-12-methylbenz[a]anthracene and its electrophilic sulfuric acid ester metabolite in preweanling rats and mice. Biochem Biophys Res Commun 144:576-582.
411. Svensson CK. (2009). Biotransformation of drugs in human skin. Drug Metab Dispos 37:247-253.
412. Takizawa D, Hiraoka H, Goto F, et al. (2005). Human kidneys play an important role in the elimination of propofol. Anesthesiology 102: 327-330.
413. Tan BS, Tiong KH, Muruhadas A, et al. (2011). CYP2S1 and CYP2W1 mediate 2-(3, 4-dimethoxyphenyl)-5-fluorobenzothiazole (GW-610, NSC 721648) sensitivity in breast and colorectal cancer cells. Mol Cancer Ther 10:1982-1992.
414. Tang SC, Sheu GT, Wong RH, et al. (2010). Expression of glutathione S-transferase M2 in stage I/II non-small cell lung cancer and alleviation of DNA damage exposure to benzo[a]pyrene. Toxicol Lett 192:316-323.
415. Tang YM, Chen GF, Thompson PA, et al. (1999). Development of an antipeptide antibody that binds to the C-terminal region of human CYP1B1. Drug Metab Dispos 27:274-280.
416. Tanihara Y, Masuda S, Katsura T, Inui K. (2009). Protective effect of concomitant administration of imatinib on cisplatin-induced nephro-toxicity focusing on renal organic cation transporter OCT2. Biochem Pharmacol 78:1263-1271.
417. Terrier P, Townsend AJ, Coindre JM, et al. (1990). An immunohisto-chemical study of pi class glutathione S-transferase expression in normal human tissue. Am J Pathol 137:845-853.
418. Testa B, Krämer SD. (2010). The biochemistry of drug metabolism: Conjugations, consequences of metabolism, influencing factors. Zürich, Switzerland: Willey-VCH.
419. Teubner W, Meinl W, Florian S, et al. (2007). Identification and localization of soluble sulfotransferases in the human gastrointestinal tract. Biochem J 404:207-215.
420. Theken KN, Deng Y, Kannon MA, et al. (2011). Activation of the acute inflammatory response alters cytochrome P450 expression and eicosanoid metabolism. Drug Metab Dispos 39:22-29.
421. Thier R, Brüning T, Roos PH, et al. (2003). Markers of genetic susceptibility in human environmental hygiene and toxicology: the role of selected CYP, NAT and GST genes. Int J Hyg Environ Health 206:149-171.
422. Thum T, Erpenbeck VJ, Moeller J, et al. (2006). Expression of xenobiotic metabolizing enzymes in different lung compartments of smokers and nonsmokers. Environ Health Perspect 114:1655-1661.
423. Thummel KE, Wilkinson GR. (1998). In vitro and in vivo drug interactions involving human CYP3A. Annu Rev Pharmacol Toxicol 38:389-430.
424. Trdan Lusin T, Roskar R, Mrhar A. (2012). Evaluation of bisphenol A glucuronidation according to UGT1A1*28 polymorphism by a new LC-MS/MS assay. Toxicology 292:33-41.
425. Tsuchiya Y, Nakajima M, Takagi S, et al. (2006). MicroRNA regulates the expression of human cytochrome P450 1B1. Cancer Res 66: 9090-9098.
426. Tukey RH, Strassburg CP. (2000). Human UDP-glucuronosyltrans-ferases: Metabolism, expression, and disease. Annu Rev Pharmacol Toxicol 40:581-616.
427. Tukey RH, Strassburg CP. (2001). Genetic multiplicity of the human UDP-glucuronosyltransferases and regulation in the gastrointestinal tract. Mol Pharmacol 59:405-414.
428. van de Kerkhof EG, de Graaf IA, Ungell AL, Groothuis GM. (2008). Induction of metabolism and transport in human intestine: Validation of precision-cut slices as a tool to study induction of drug metabolism in human intestine in vitro. Drug Metab Dispos 36: 604-613.
429. van Eijl S, Zhu Z, Cupitt J, et al. (2012). Elucidation of xenobiotic metabolism pathways in human skin and human skin models by proteomic profiling. PLoS One 7:e41721.
430. van Herwaarden AE, Wagenaar E, Karnekamp B, et al. (2006). Breast cancer resistance protein (Bcrp1/Abcg2) reduces systemic exposure of the dietary carcinogens aflatoxin B1, IQ and Trp-P-1 but also mediates their secretion into breast milk. Carcinogenesis 27:123-130.
431. van Midwoud PM, Merema MT, Verpoorte E, Groothuis GM. (2010). A microfluidic approach for in vitro assessment of interorgan interactions in drug metabolism using intestinal and liver slices. Lab Chip 10:2778-2786.
432. Vasconcelos-Nóbrega C, Colaço A, Lopes C, Oliveira PA. (2012). Review: BBN as an urothelial carcinogen. In Vivo 26:727-739.
433. Vaziri SA, Hughes NC, Sampson H, et al. (2001). Variation in enzymes of arylamine procarcinogen biotransformation among bladder cancer patients and control subjects. Pharmacogenetics 11:7-20.
434. Vecchini F, Mace K, Magdalou J, et al. (1995). Constitutive and inducible expression of drug metabolizing enzymes in cultured human keratinocytes. Br J Dermatol 132:14-21.
435. Veiga-da-Cunha M, Tyteca D, Stroobant V, et al. (2010). Molecular identification of NAT8 as the enzyme that acetylates cysteine S-conjugates to mercapturic acids. J Biol Chem 285:18888-18898.
436. Villard PH, Sampol E, Elkaim JL, et al. (2002). Increase of CYP1B1 transcription in human keratinocytes and HaCaT cells after UV-B exposure. Toxicol Appl Pharmacol 178:137-143.
437. Vogel C, de Sousa Abreu R, Ko D, et al. (2010). Sequence signatures and mRNA concentration can explain two-thirds of protein abundance variation in a human cell line. Mol Syst Biol 6:1-9.
438. Völkel W, Friedewald M, Lederer E, et al. (1998). Biotransformation of perchloroethene: Dose-dependent excretion of trichloroacetic acid, dichloroacetic acid, and N-acetyl-S-(trichlorovinyl)-L-cysteine in rats and humans after inhalation. Toxicol Appl Pharmacol 153:20-27.
439. Vyas PM, Roychowdhury S, Khan FD, et al. (2006a). Enzyme-mediated protein haptenation of dapsone and sulfamethoxazole in human keratinocytes: I. Expression and role of cytochromes P450. J Pharmacol Exp Ther 319:488-496.
440. Vyas PM, Roychowdhury S, Koukouritaki SB, et al. (2006b). Enzyme-mediated protein haptenation of dapsone and sulfamethoxazole in human keratinocytes: II. Expression and role of flavin-containing monooxygenases and peroxidases. J Pharmacol Exp Ther 319: 497-505.
441. Walker K, Ginsberg G, Hattis D, et al. (2009). Genetic polymorphism in N-Acetyltransferase (NAT): Population distribution of NAT1 and NAT2 activity. J Toxicol Environ Health B Crit Rev 12:440-472.
442. Walraven JM, Barker DF, Doll MA, Hein DW. (2007). Tissue expression and genomic sequences of rat N-acetyltransferases rNat1, rNat2, rNat3, and Functional characterization of a novel rNat3*2 genetic variant. Toxicol Sci 99:413-421.
443. Wang K, Guengerich FP. (2013). Reduction of aromatic and heterocyclic aromatic N-hydroxylamines by human cytochrome P450 2S1. Chem Res Toxicol 26:993-1004.
444. Wang SL, He XY, Hong JY. (2005). Human cytochrome p450 2s1: Lack of activity in the metabolic activation of several cigarette smoke carcinogens and in the metabolism of nicotine. Drug Metab Dispos 33:336-340.
445. Watabe T, Ishizuka T, Isobe M, Ozawa N. (1982). A 7-hydroxymethyl sulfate ester as an active metabolite of 7, 12-dimethylbenz[alpha] anthracene. Science 215:403-405.
446. Wei HB, Han XY, Fan W, et al. (2003). Effect of retinoic acid on cell proliferation kinetics and retinoic acid receptor expression of colorectal mucosa. World J Gastroenterol 9:1725-1728.
447. Wei Y, Wu H, Li L, et al. (2012). Generation and characterization of a CYP2A13/2B6/2F1-transgenic mouse model. Drug Metab Dispos 40: 1144-1150.
448. Weibel H, Hansen J. (1989). Penetration of the fragrance compounds, cinnamaldehyde and cinnamyl alcohol, through human skin in vitro. Contact Dermatitis 20:167-172.
449. Whitbread AK, Tetlow N, Eyre HJ, et al. Characterization of the human Omega class glutathione transferase genes and associated polymorphisms. Pharmacogenetics 13:131-144.
450. Wild PJ, Kunz-Schughart LA, Stoehr R, et al. (2005). High-throughput tissue microarray analysis of COX2 expression in urinary bladder cancer. Int J Oncol 27:385-391.
451. Wilkin JK, Stewart JH. (1987). Substrate specificity of human cutaneous alcohol dehydrogenase and erythema provoked by lower aliphatic alcohols. J Invest Dermatol 88:452-454.
452. Willey JC, Coy EL, Frampton MW, et al. (1997). Quantitative RT-PCR measurement of cytochromes p450 1A1, 1B1, and 2B7, microsomal epoxide hydrolase, and NADPH oxidoreductase expression in lung cells of smokers and nonsmokers. Am J Respir Cell Mol Biol 17: 114-124.
453. Williams PL, James RC, Roberts SM. (2000). Principles of toxicology: Environmental and industrial applications. New York: Wiley-Interscience Publication, John Wiley & Sons, Inc.
454. Windmill KF, Gaedigk A, Hall PM, et al. (2000). Localization of N-acetyltransferases NAT1 and NAT2 in human tissues. Toxicol Sci 54:19-29.
455. Windmill KF, McKinnon RA, Zhu X, et al. (1997). The role of xenobiotic metabolizing enzymes in arylamine toxicity and carcino-genesis: Functional and localization studies. Mutat Res 376:153-160.
456. Wu S, Moomaw CR, Tomer KB, et al. (1996). Molecular cloning and expression of CYP2J2, a human cytochrome P450 arachidonic acid epoxygenase highly expressed in heart. J Biol Chem 271:3460-3468.
457. Wu ZL, Sohl CD, Shimada T, Guengerich FP. (2006). Recombinant enzymes overexpressed in bacteria show broad catalytic specificity of human cytochrome P450 2W1 and limited activity of human cytochrome P450 2S1. Mol Pharmacol 69:2007-2014.
458. Xie W, Yeuh MF, Radominska-Pandya A, et al. (2003). Control of steroid, heme, and carcinogen metabolism by nuclear pregnane X receptor and constitutive androstane receptor. Proc Natl Acad Sci USA 100:4150-4155.
459. Yaghi A, Bradbury JA, Zeldin DC, et al. (2003). Pulmonary cytochrome P-450 2J4 is reduced in a rat model of acute Pseudomonas pneumonia. Am J Physiol Lung Cell Mol Physiol 285:L1099-L1105.
460. Yang LM, Li XH, Bao CF. (2012). Glutathione S-transferase P1 and DNA polymorphisms influence response to chemotherapy and prognosis of bone tumors. Asian Pac J Cancer Prev 13:5883-5886.
461. Yao L, Wang HC, Liu JZ, Xiong ZM. (2013). Quantitative assessment of the influence of cytochrome P450 2C19 gene polymorphisms and digestive tract cancer risk. Tumour Biol 34:3083-3091.
462. Yengi LG, Xiang Q, Pan J, et al. (2003). Quantitation of cytochrome P450 mRNA levels in human skin. Anal Biochem 316:103-110.
463. Yin ZL, Dahlstrom JE, Le Couteur DG, et al. (2001). Immunohistochemistry of omega class glutathione S-transferase in human tissues. J Histochem Cytochem 49:983-987.
464. Ying-Hao S, Qing Y, Lin-Hui W, et al. (2002). Monitoring gene expression profile changes in bladder transitional cell carcinoma using cDNA microarray. Urol Oncol 7:207-212.
465. Yourick JJ, Bronaugh RL. (2000). Percutaneous penetration and metabolism of 2-nitro-p-phenylenediamine in human and fuzzy rat skin. Toxicol Appl Pharmacol 166:13-23.
466. Yu MC, Skipper PL, Tannenbaum SR, et al. (2002). Arylamine exposures and bladder cancer risk. Mutat Res 506-507:21-28.
467. Yu Z, Huse LM, Adler P, et al. (2000). Increased CYP2J expression and epoxyeicosatrienoic acid formation in spontaneously hypertensive rat kidney. Mol Pharmacol 57:1011-1020.
468. Yue QY, Odar-Cederlöf I, Svensson JO, Säwe J. (1988). Glucuronidation of morphine in human kidney microsomes. Pharmacol Toxicol 63: 337-341.
469. Zalko D, Jacques C, Duplan H, et al. (2011). Viable skin efficiently absorbs and metabolizes bisphenol A. Chemosphere 82: 424-430.
470. Zanger UM, Schwab M. (2013). Cytochrome P450 enzymes in drug metabolism: Regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol Ther 138:103-141.
471. Zeldin DC, Foley J, Goldsworthy SM, et al. (1997). CYP2J subfamily cytochrome P450s in the gastrointestinal tract: Expression, localization, and potential functional significance. Mol Pharmacol 51: 931-943.
472. Zenser TV, Lakshmi VM, Davis BB. (1998). N-glucuronidation of benzidine and its metabolites. Role in bladder cancer. Drug Metab Dispos 26:856-859.
473. Zenser TV, Lakshmi VM, Hsu FF, Davis BB. (2002). Metabolism of N-acetylbenzidine and initiation of bladder cancer. Mutat Res 506-507:29-40.
474. Zhang J, Cashman JR. (2006). Quantitative analysis of FMO gene mRNA levels in human tissues. Drug Metab Dispos 34:19-26.
475. Zhang JY, Wang Y, Prakash C. (2006). Xenobiotic-metabolizing enzymes in human lung. Curr Drug Metab 7:939-948.
476. Zhang QY, Dunbar D, Ostrowska A, et al. (1999). Characterization of human small intestinal cytochromes P-450. Drug Metab Dispos 27: 804-809.
477. Zhang X, D'Agostino J, Wu H, et al. (2007). CYP2A13: Variable expression and role in human lung microsomal metabolic activation of the tobacco-specific carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone. J Pharmacol Exp Ther 323:570-578.
478. Zhang Y, Gonzalez V, Xu MJ. (2002). Expression and regulation of glutathione S-transferase P1-1 in cultured human epidermal cells. J Dermatol Sci 30:205-214.
479. Zhang Z, Yu XY, Zhang GJ, et al. (2012). Low microsomal epoxide hydrolase expression is associated with bladder carcinogenesis and recurrence. Asian Pac J Cancer Prev 13:521-525.
480. Zhou SF. (2008). Drugs behave as substrates, inhibitors and inducers of human cytochrome P450 3A4. Curr Drug Metab 9:310-322.
481. Zhu LR, Thomas PE, Lu G, et al. (2006). CYP2A13 in human respiratory tissues and lung cancers: An immunohistochemical study with a new peptide-specific antibody. Drug Metab Dispos 34: 1672-1676.
482. Zimniak P. (1993). Dubin-Johnson and Rotor syndromes: Molecular basis and pathogenesis. Semin Liver Dis 13:248-260.